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 Anthropologists provide a valuable service to the medico-legal community.  They 
are tasked with creating a biological profile and helping with the ultimate identification 
of unknown remains.  This can often be a difficult task when the anthropologists require 
something to which they can compare the biological profile and create a small group of 
potential matches.  This endeavor can be greatly enhanced by access to medical patient 
databases and identification techniques which are able to utilize specific disease 
databases in conjunction with the biological profile. 
 The research presented here explores the genetic connection between the eye 
disease Age-Related Macular Degeneration (AMD), and the bone disease Ossification of 
the Posterior Longitudinal Ligament (OPLL) as a new avenue of identification.  The 
research conducted looked at the specific genetic marker that connects the two diseases, 
the interaction of this genetic risk factor with other risk genes in AMD, and the 
prevalence and presentation of OPLL in non-Asian populations.   
 The results of the project provided a great deal of insight into a possible 
therapeutic target for AMD and suggests that the previously reported statistics on OPLL 
both in, and out, of Asia are grossly underestimated, thus the disease should be 
reexamined in all populations throughout the world.  In addition, the results and 
parameters of this research advocate future research into an identification method based 
on the genetic connection between these two diseases.  
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The Need for More Avenues of Identification 
Forensic anthropology, especially osteological analysis, has become vital to 
medico-legal cases in which remains are highly desiccated or void of soft tissue.  One of 
the main roles of the anthropologist in these cases is the attempted identification of the 
deceased through the implementation of identification methodologies and the creation of 
a biological profile of the remains.  Unfortunately, there are only a few databases to 
which researchers can compare their findings to help identify the deceased.  Without the 
ability to compare the biological profiles of unidentified remains to potential matches, it 
is very difficult to give a name to the unknown remains.  At the same time, there are 
many medical patient databases with extensive areas of information that have yet to be 
utilized by outside sources, especially forensic investigators.  The creation and 
exploration of innovative approaches to identification in forensic anthropology is vital to 
both the growth of the field and future attempts to name the unidentified in medico-legal 
situations.  The aim of this research is to demonstrate that collaboration between genetic 
and forensic researchers can expand skeletal identification techniques and provide new 
avenues for individual identification through the use of specific medical databases and 






Age-Related Macular Degeneration 
Utilizing disease-specific databases may provide a much needed tool for forensic 
anthropologists in their work to identify the unknown.  By using a medical database 
associated with the eye disease Age-Related Macular Degeneration (AMD), forensic 
anthropologists have the chance to improve their identification and individualization 
process.  AMD is an inflammatory, late-onset, progressive, degenerative disease that 
primarily affects the macula, or central region, of the human retina - the light-sensitive 
tissue lining the inner part of the eye – and is the leading cause of blindness in the US 
(DeAngelis et al., 2004; Swaroop et al., 2009; Klein et al., 2011).  AMD causes minor to 
advanced central vision loss in individuals over 50 years and currently affects over 20 
million people worldwide, with 1.75 million US citizens having advanced forms of the 
disease in at least one eye (Friedman et al., 2004; EDPRG, 2011).  In its early stages it 
causes only minimal visual impairment, but may lead to loss of high-resolution central 
vision in severe cases, which in turn leads to loss of the ability to drive, recognize faces, 
and read.  As the population ages, AMD will be a more common cause of vision loss than 
diabetic eye disease and glaucoma combined, one of the primary reasons being that the 
prevalence of AMD increases dramatically with age.  
 Early stages of the disease are characterized by yellowish deposits in the macula 
and peripheral retina, known as drusen, and generalized retinal pigment epithelium (RPE) 
changes (Jager et al., 2008).  Drusen can be small (under 63μm), medium (63-124μm), or 
large (over 124μm), and have been clinically classified as hard, soft, cuticular, calcified, 
and most recently, reticular (Jager et al, 2008; Schmitz-Valckenberg et al., 2011).  The 
presence of a few medium-sized drusen is the hallmark sign of early AMD, however, 
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there are two recognized forms of advanced AMD which do not solely rely on the 
presence of drusen for characterization.  Dry AMD is the less severe form and accounts 
for 90% of cases, and wet AMD is the more severe form and only accounts for 10% of 
cases (DeAngelis et al., 2011).  Dry AMD results in geographic atrophy, which is the 
disruption of the natural geography of the retina associated with a slow, progressive 
deterioration of the RPE, resulting in the loss of photoreceptors in the localized area 
(Swaroop et al., 2007).  Wet AMD is associated with the neovascular presentation of the 
disease, which is the creation of new, and secretion of existing blood vessels (Swaroop et 
al., 2007; Feehan et al., 2011).  The progression of AMD is classified into four categories 














Figure 1. The AREDS stages of AMD.  Clinical fundus photo of a right human retina (A) 
with the yellow macular region identified.  B is the early to intermediate stages of AMD 
classified as categories 2-3 on the AREDS scale, with drusen present.  In C there is 
evidence of advanced dry AMD in the form of geographic atrophy; an AREDS level 4.  
D shows advanced, neovascular, wet AMD as characterized by the red mass near the 








no signs of disease to advanced AMD and are characterized by increased abnormalities 
present at and around the macula. 
Extensive research into the etiology of AMD has indicated that there are both 
epidemiologic and genetic risk factors to the disease.  The most important environmental 
factor is smoking, with individuals smoking 10 pack-years or more having a 144-fold 
increased risk of developing AMD over those who have not smoked to such a degree 
(DeAngelis et al., 2007).  Other significant risk factors include: age, body mass index, 
dietary fat intake (especially lard and solid fats), hypertension, low dietary intake of 
antioxidants and zinc, serum cholesterol/use of cholesterol lowering medications, alcohol 
consumption, diabetes mellitus, sunlight exposure, iris color, and family history (Klein et 
al., 2004; Choi et al., 2011; DeAngelis et al., 2011; Ngai et al., 2011).  Research has also 
revealed factors which are protective against the development of AMD.  Evidence has 
suggested that consumption of omega-3 fatty acids in association with antioxidants, as 
well as Vitamin D intake may be protective against AMD development and neovascular 
AMD, respectively (Kishan et al., 2011; Morrison et al., 2011).   
Genetic studies have identified Compliment Factor H (CFH) as a major risk gene 
located on chromosome 1 (Klein et al., 2005; Haines et al., 2005; Edwards et al., 2005).  
Further analysis has shown an even stronger additive genetic component with the 
influence of Age-Related Maculopathy Susceptibility 2 /HTRA Serine Peptidase 1 
(ARMS2/HTRA1) on chromosome 10 (Yang et al., 2006; DeAngelis et al., 2008; 
Andreoli et al., 2009).  Specifically, the ARMS2 risk allele is associated with earlier and 
more severe neovascular AMD (Leveziel et al., 2010).  In fact, the chromosome 10 
region where HTRA1 resides is thought to have the strongest association with risk of 
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neovascular AMD among any of the currently accepted AMD genetic risk factors (AMD 
Gene Consortium, 2013).  CFH is thought to be most influential in the onset of AMD, 
while the combination of CFH and ARMS2/HTRA1 account for the advancement of 
AMD through the AREDS stages (Zhang et al., 2008; Farwick et al., 2009).  In addition, 
the genes ROBO1 and RORA have also been shown to interact with both CFH and 
ARMS2/HTRA1 and significantly increase the risk of developing AMD (Schaumberg et 
al., 2010; Jun et al., 2011).  Overall, the genetic evidence strongly suggests the role of 
many genes and genetic factors in the susceptibility if individuals to both forms of AMD 
(Sturgill et al., 2006; Kim et al., 2008; DeAngelis et al., 2011; Hong et al., 2011). 
The earliest suggestion of genetic predisposition to the disease was identified 
through familial aggregation studies that showed AMD clusters in families, i.e., patients 
with AMD are more likely to have relatives with AMD (Silvestri et al., 1994; Seddon et 
al., 1997).  While age is the biggest risk factor for developing AMD, an average person is 
3-6 times more likely to have AMD if he/she has an affected parent or sibling.  Later twin 
studies showed that AMD concordance is greater for identical twins than fraternal twins 
(Swaroop et al., 2009; DeAngelis et al., 2011).  Studies also showed that White 
individuals are at higher risk of developing the disease than any other ethnic group (Klein 
et al., 2006; Klein et al., 2011).  These early genetic studies prompted a search of the 
genome for genes that are working differentially between the different types of AMD and 
between those with the disease and those without, even among siblings.  A remarkable 
convergence of clinical, biological, and genetic data has made AMD one of the best 





Connecting Bone and Eye Disease 
Recent research on the genetic pathways related to AMD has identified the gene 
Bone Morphogenetic Protein 4 (BMP4) as being associated with previously identified 
major risk factors of the disease (Zhu et al., 2009a; Zhu et al., 2009b; Silveira et al., 
2010; Xu et al., 2011).  This gene plays an important role in the onset of endochondral 
bone formation and fracture repair in humans.  Alterations in expression of the gene, as 
well as specific variants found within the gene, have been associated with a variety of 
bone diseases.  Specifically, the single-nucleotide polymorphism (SNP), or DNA 
sequence variation of a single base, rs17563 in BMP4 has been associated with the bone 
disease ossification of the posterior longitudinal ligament (OPLL) (Meng et al., 2010).  
OPLL occurs when the ligament running along the vertebral bodies within the spinal 
column starts to ossify, or become bone, and impinge on the spinal cord potentially 
causing neurological complications (Singh et al., 2004).   
The association of both an identifiable skeletal abnormality and a well 
documented eye disease with the same risk gene makes OPLL a prime candidate for an 
avenue of forensic identification through a combined physical and genetic methodology.  
With approximately 10% of the population over 40 years, and 30% of the population over 
75 years presenting with some form of the disease, it is projected that about 2.95 million 
Americans will have advanced AMD by the year 2020 (Klein et al., 1992; Friedman et 
al., 2004; EDPRG, 2011).  As a result, there is a rich knowledge base on the individuals 
who suffer from this disease throughout the country.  Because of the disease’s association 
with BMP4, forensic anthropologists have the chance to utilize this wealth of data linked 
to AMD (i.e., medical records) to facilitate the identification of human remains.   
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Format of Research 
 The intent of this research is to show that, given the genetic association between 
AMD and OPLL via BMP4, the identification of OPLL on a set of remains can allow the 
forensic anthropologist to direct a DNA study in search of the SNP in the BMP4 gene 
related to AMD.  Upon finding the SNP, analysis would continue in search of the other 
known risk SNPs which interact with BMP4, and suggest that the individual does have 
AMD.  The anthropologist can then search the local AMD patient databases, using the 
biological profile, to advance the identification process by composing a subset of 
potential matches.   
This research is intended to be applicable for use by forensic anthropologists in 
the United States, as a result, it focuses on the two largest population groups in the US 
according to the 2010 census which comprise 85% of the total population, Whites and 
Blacks (Humes et al., 2011).  Primary interest rests with individuals of European ancestry 
(referred to as “Whites” for the remainder of the paper) as they represent the majority of 
individuals in the United States (72.4%), they are the highest at-risk group for 
development of AMD (Klein et al., 2011), and they are believed to be the population with 
the lowest prevalence of OPLL (Matsunaga and Sakou, 2006b).  The high prevalence of 
AMD among Whites provides a great deal of information on those with the disease, while 
the proposed low prevalence of OPLL means that this identification method will actually 
be useful in narrowing down the pool of potential matches from the wider population.  
The addition of Black individuals in the skeletal study, as well as an Asian population in 
the genetic analysis, provides the chance for a comparative study and the observation of 
any differences between populations. 
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 The research presented here was conducted in two main avenues of analysis.  
First, a genetic analysis was conducted with the BMP4 gene in relation to AMD among 
four separate cohorts.  Variation in the gene was analyzed for direct risk of AMD and for 
its interaction with other known risk factors of the disease.  This was done to confirm that 
BMP4 is in fact functioning in the pathogenesis of AMD and that the SNP associated 
with OPLL, rs17563, was the risk factor tying these two diseases together.  Secondly, 
OPLL has only been extensively studied in Asians, in a clinical setting.  To better 
understand the prevalence and characteristics of this disease in America, analysis was 
conducted on a 20th Century skeletal population of White and Black individuals.  This 
analysis was able to clarify the utility of the proposed identification method among the 
majority of the US population.  The following chapters will introduce the two main 
research aspects of this work, BMP4 and OPLL, and present the results of each analysis.  
The OPLL-BMP4-AMD Identification Method section will discuss how these results 
affect the applicability of the proposed method and where to direct future research.  The 
Conclusion shall present the final analysis of the original hypothesis and discuss what 
this research has brought to the field of anthropology, beyond its original intent. 
 
 
Improving Identification Through Collaboration 
There are currently over 40,000 unidentified remains in the United States (Ritter, 
2007); carrying out innovative research such as this can help identify these remains and 
bring closure to the families of the missing. This project is an original exploration of the 
use of disease-specific medical databases for forensic identification.  The research 
integrates traditional forensic anthropological identification techniques with the use of 
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disease-specific patient genetic databases to create a novel avenue of forensic 
identification.  This work can advance the knowledge base of forensic anthropologists by 
suggesting that features not previously considered individuating, such as OPLL, can in 
fact become vital parts of the identification process with a little background research and 
collaboration with other scientists.  This research also has the potential to develop better 
communication and understanding between forensic anthropologists and medical 
researchers. 






As was mentioned in the Introduction section of this paper, this research is a 
result of inquiry into the genetic network of AMD and the identification of BMP4 as a 
risk allele for this important disease.  Recent research on the genetic pathways related to 
AMD has identified BMP4 in the gene network related to the RORA-ROBO1-HTRA1 
triumvirate, which conveys the highest collective risk for AMD (Silveira et al., 2010).  
This RORA-ROBO1-HTRA1 network is a visualization of the connection between the 
genes implicated in AMD, as identified through previous research and published through 
the National Center for Biotechnology Information (NCBI).  This pathway (Figure 2) 
presents genes which have been identified numerous times as having an important 
association with, and are generally accepted to increase the risk of AMD.  It also begins 
to explain the connections between the numerous candidate genes.  BMP4 is identified as 
having a suspected direct association with HTRA1. This is the first method of inquiry 
into the pathogenesis of AMD which identified BMP4 as a potential gene of interest 
(Silveira et al., 2010).  The presence of BMP4 in this network suggests that it plays an 
important role in connection with the RORA-ROBO1-HTRA1 triumvirate as vital to the 
pathogenesis of AMD.  If that is truly the case, identification of variants within this gene 
that are direct risk factors for AMD and that are associated with OPLL, such as SNP 









Figure 2. The RORA-ROBO1-HTRA1 network. This network is constructed from the 
available data on candidate genes associated with the eye disease AMD.  The genes 
within the grey boxes have been identified numerous times as having an important 
association with, and are generally accepted to increase the risk of AMD.  Connections 
between genes identified with hash marks represent un-tested or tenuous associations.  
Solid lines represent direct, or suspected direct interaction between genes.  You can see 
BMP4 identified in the red box as having a suspected direct association with HTRA1 
when discussing AMD.  Modified from Silveira et al, 2010. 
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these two diseases and provide the basis for the proposed method of identification.   
 
Explanation of the BMP4 Gene 
The BMP4 gene identified through this network is a regulatory molecule that 
operates throughout development in mesoderm induction, tooth development, limb 
formation, bone induction, and fracture repair (Kochanowska et al., 2007; Bakrania et al., 
2008; Pachori et al., 2010).  BMP4 is a member of the bone morphogenetic protein 
(BMP) family which originally derived its name from the proteins’ ability to induce bone 
and cartilage formation (Urist, 1965; Wozney et al., 1988).  However, BMPs are 
expressed in a variety of tissues in addition to bone, including cartilage, blood vessels, 
skin, heart, kidney, liver, lung, and the retina (Massague and Chen, 2000; Chen et al., 
2004).  In addition, BMPs exhibit a wide range of biological activities, from the 
formation and patterning of various tissues to the morphogenesis of a number of organs, 
and BMP-mediated signaling affects diverse cellular processes such as proliferation, 
differentiation, migration, and apoptosis (Hogan, 1996).  BMPs are part of the 
transforming growth factor-beta (TGF-β) superfamily which consists of secretory 
signaling molecules responsible for controlling structure-related cell activities and play 
essential roles in embryonic development (Bakrania et al., 2008).  
The human BMP4 gene is located on chromosome 14, at 14q22-q23 (Tabas et al., 
1993).  The gene contains five exons: exon 1A, exon 1B, exon 2, 3, and 4 (van den 
Wijngaard et al., 1996; Shore et al., 1998; Helvering et al., 2000).   Exons 1A and 1B are 
alternative start sites for the various BMP4 variants, thus each variant only has four 
exons.  There are three mRNA variants for this gene and they all encode the same 
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protein, derived from the sequences of only exon 3 and exon 4.  Variants 1 (Figure 3) and 
2 are derived from promoter A, located upstream of exon 1A, and variant 3 is derived 
from promoter B, located upstream of exon 1B (van den Wijngaard et al., 1999; van den 
Wijngaard et al., 2000; Thompson et al., 2003).  Evidence indicates that there has been 
strong conservation of variation of this gene within species: 95% (+) identity among all 
of the disease SNPs within members of the primate family, and 75% (+) identity among a 
number of mammals varying from livestock (cattle, sheep, etc.) to elephants (Dardenne, 
2012). In addition, the human BMP4 gene and mouse BMP4 gene share a similar 
structure and the coding regions are highly homologous, providing for very informative 
murine studies of the gene (Shore et al., 1998). 
 
BMP4 and the Eye 
BMP4 is particularly important in ocular development, although research has 
reported the expression of numerous BMPs (BMP2, BMP3, BMP4, BMP5, BMP6, and 
BMP7) in ocular tissues (Wordinger and Clark, 2007).  In chick models, BMP4 signaling 
has been found to control the size of the dorsal optic cup by regulating cell proliferation 
and apoptosis, and in general, BMPs have been shown to be necessary, and sufficient, for 
RPE development in vivo (Behesti et al., 2006; Muller et al., 2007).  In murine models, 
lens induction is absent in mice with homozygous disruption of BMP4, and BMP4+/- 
heterozygotes develop a variety of ocular abnormalities including elevated intraocular 
pressure, anterior segment dysgenesis, and posterior segment abnormalities (Furuta and 




Figure 3: BMP4 gene schematic. Representation of the longest variant of the BMP4 gene constructed from the available literature.  
The location, direction, and exons of the gene are visible, as well as the SNPs that were assayed for this research and the SNPs 




aplasia and microphthalmia in Msx2 transgenic mice (Wu et al., 2003).  In rats, BMP4 
has been shown to mediate apoptosis of capillary endothelial cells during pupilary 
membrane regression (Kiyono and Shibuya, 2003).  However, BMP4 has also been 
associated with positive effects in the eye, including short-lived protective effects on 
retinal neurons from NMDA-mediated excitotoxicity, suppression of damage-induced 
proliferation of Muller glia, and the inhibition of exaggerated RPE proliferation in wound 
repair (Mathura et al., 2000; Fischer et al., 2004).  
In regards to eye disease, BMP4 has long been implicated in the pathogenesis of 
glaucoma, especially in regards to elevated intraocular pressure, and it is a strong 
candidate gene for Axenfeld-Rieger Anomaly and other conditions associated with 
glaucoma (Chang et al., 2001; Wordinger et al., 2007).  Recently, studies out of the 
University of Southern California indicated that BMP4 may be involved in the 
determination of which late form of AMD an individual develops.  This team of 
researchers demonstrated that BMP4 was differentially expressed in the macular tissues 
of “dry” and “wet” AMD patients (Zhu et al., 2009a; Zhu et al., 2009b; Xu et al., 2011).  
In the RPE and choroid tissues of the macula in late dry AMD, BMP4 expression was 
increased.  Oxidative stress increased BMP4 expression in these RPE cells and BMP4 
acted as a mediator in oxidative stress-induced RPE senescence (Zhu et al., 2009a).  In 
contrast to the up-regulation of BMP4 in dry AMD, choroidial neovascular (CNV), or 
wet, AMD is characterized by a low expression of BMP4 in the RPE cells (Xu et al., 
2011).  Murine models show that BMP4 expression is decreased in laser-induced CNV 
mice when tumor necrosis factor (TNF) levels are high, and rebounds when TNF levels 
are low (Xu et al., 2011).  Thus, BMP4 may be involved in the molecular switch 
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determining which phenotypic pathway is taken in the progression from early to late 
stage AMD. 
 
BMP4 and Human Disease 
There are a number of diseases outside the eye which are also associated with this 
gene, such as HFE hemochromatosis penetrance, scoliosis, cleft palate with or without 
cleft lip, oligodontia, and juvenile leukemia, among others (Figure 4) (Milet et al., 2007; 
Suzuki et al., 2009; Simón-Sánchez et al., 2009; Zhang et al., 2009; Hi et al., 2010; Suazo 
et al., 2010; Mórocz et al., 2011; Olk-Batz et al., 2011; Mu et al., 2012).  In general, 
mutations in BMP4 are known to cause eye, brain, and digit abnormalities (Bakrania et 
al., 2008).  BMP4 can also act as an antiangiogenic factor by inducing apoptosis (Fujita et 
al., 1999; Kiyono and Shibuya, 2003; Fukuda et al., 2006; Kiyono and Shibuya, 2006) 
and cell senescence (Buckley et al., 2004; Su et al., 2009; Zhu et al., 2009a).  BMP4 has 
been shown to be over expressed in a number of diseases including lumbar and hindlimb 
fusion, hypoxia-induced pulmonary hypertension, colorectal cancer, and fibrodysplasia 
ossificans progressiva, which is a genetic disorder of axial and appendicular skeletal 
malformation and progressive heterotopic ossification (Shafritz et al., 1996; Shore et al., 
1998; Blaszczyk et al., 2003; Frank et al., 2005; Feldman et al., 2007; Houlston et al., 
2008; Fernandez-Rozadilla et al., 2010; Lubbe et al., 2010; Niittymaki et al., 2011; Tang 
et al., 2011; Kaplan et al., 2012; Kaplan et al., 2012; Lubbe at al., 2012; Suzuki et al., 
2012; Fernandez-Rozadilla et al., 2013).  BMP4 has been implicated in ovarian cancer 
specifically, and as a potential therapeutic target in cancer cell research in general, and a 
strong expression of BMP4 in malignant melanomas has been shown to promote cell 
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Figure 4. BMP4 and human disease. Diseases associated with BMP4 variants and 




invasion and migration (Kochanowska et al., 2002; Shepherd and Nachtigal, 2003; 
Rothhammer et al., 2005; Rothhammer et al., 2007; Theriault et al., 2007; Shepherd et al., 
2008; Kallioniemi et al., 2012; Peart et al., 2012).  There is strong evidence that 
individuals with a BMP4 disease risk allele also have, or are more susceptible to, other 
diseases associated with the gene (such as those described above). 
One BMP4 SNP in particular, rs17563, is associated with a number of diseases 
including cutaneous melanoma, otosclerosis (abnormal boney growth near the middle 
ear), and ossification of the posterior longitudinal ligament of the cervical spine (OPLL) 
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(Figure 4) (Schrauwen et al., 2008; Capasso et al., 2009; Meng et al., 2010; Ren et al., 
2012a).  Focusing on OPLL, it has been shown that the T allele in rs17563 among Han 
Chinese males increases the risk of development of OPLL and causes more extensive 
OPLL throughout the cervical spine (Meng et al., 2010; Ren et al., 2012a).  More 
generally, BMP4 has been identified as a risk gene through large-scale screenings of 
various populations, suggesting that there is a ubiquitous OPLL risk factor in this gene 
across populations (Furushima et al., 2002; Tanno et al., 2003).  OPLL is the focus of this 
research because of its identifiable, physical manifestation in the skeleton, and rs17563 is 
a prime target for the connection between OPLL and AMD because of its previously 
reported multidisease association.   
 
Genetic and Interaction Analyses 
Introduction 
While the previous research highlighting the involvement of BMP4 in the 
advancement of AMD is encouraging for this research, the identification method 
proposed here requires more than just dysregulation of gene expression as a risk factor.  
In order for BMP4 to be a target of identification, the risk factor for AMD has to be the 
identifiable variant, rs17563, which is directly associated with risk of OPLL, or in linkage 
with rs17563.  Linkage, or linkage disequilibrium (LD), refers to certain combinations of 
alleles being inherited together more often than would be expected by random chance.  
Thus, this method is applicable whether the two diseases share a common risk allele or if 
the risk alleles are in LD (therefore more likely to be seen and inherited together).  
However, in order to exhaust all possibilities of BMP4 involvement in AMD, a number 
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of SNPs were selected to capture the full variation within the gene to test for direct 
association between specific BMP4 loci and risk of AMD, as well as, interaction between 




This study was comprised of four cohorts, two sibling cohorts and two unrelated 
cohorts.  A subset of the New England Sibling Cohort (NESC) (n=418), and an additional 
sibling cohort provided by Giuliana Silvestri (GSSibs) from Belfast, Northern Ireland 
(n=119) comprise the related study groups.  Two additional cohorts consisting of 436 
unrelated individuals from central Greece (Greeks) and 1333 unrelated individuals from 
Korea (Koreans) were also studied.  The two sibling cohorts and the Greek cohort were 
comprised entirely of White individuals.   Details of recruitment, diagnostic criteria and 
subject classification for the NESC are described elsewhere (DeAngelis et al., 2007; 
Silveira et al., 2010).  But in brief, at least one individual from each family had the 
neovascular (wet) form of AMD in at least one eye after excluding patients with a retinal 
pigment epithelium detachment, myopia, ocular histoplasmosis syndrome, angioid 
streaks, choroidal rupture, any hereditary retinal diseases other than AMD, and previous 
laser treatment for retinal conditions other than AMD.  All but 87 sibling pairs in the 
original NESC cohort were discordant for AMD.  The Greek cohort was enrolled at the 
University Hospital of Larissa outpatient medical clinics in central Greece. The diagnosis 
of AMD in this cohort was confirmed by optical coherence tomography and fluorescent 
angiography (DeAngelis et al., 2007; Silveira et al., 2010).   
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Both the GSSibs and Koreans are newly composed patient populations and recent 
additions to the DeAngelis Lab’s collection of cohorts.  As such, the collaborators from 
Ireland and South Korea have yet to provide detailed reports on their patient participation 
protocol.  Both cohorts were comprised of individuals being treated for AMD at 
registered medical clinics, and due to commonly accepted practices in AMD research, the 




Initially, four BMP4 SNPs (rs12898159, rs2761880, rs2761884, and rs2855529) 
were genotyped on two cohorts: a subset of the NESC sibling cohort (n=418) and the 
Greek cohort (n=436).  Linkage disequilibrium between the genotyped SNPs was 
determined using Haploview.  Linkage disequilibrium among the SNPs was similar 
between disease subtypes (not shown) and is shown for the NESC cohort in Figure 5.   
SNPs rs2761884 and rs2855529 were shown to be in complete LD, but the rest of 
the SNPs were not in high LD (r2<0.8).  After the primary SNP selection, the tagging 
SNP rs17563 (which is also a coding SNP) and the SNP rs4898820, which represents the 
variation from the second LD block in ABI SNPBrowser, were genotyped to cover the 
remainder of the variation within the BMP4 gene.  
All SNPs were tested for their association with AMD and its subtypes using both 
conditional logistic regression (CLR) and generalized estimating equations (GEE) for the 
related individuals, and logistic regression for the unrelated cohorts in SAS, testing each 
genetic model.  SNPs showing evidence of association in the preliminary analysis were 
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Figure 5. Linkage Disequalibrium (LD) among the NESC sibling cohort. 
 
then genotyped in the unrelated Korean cohort and the additional sibling cohort (GSSibs).  
Meta-analysis of the cohorts was performed using Comprehensive Meta-Analysis v2.  
Adjustments were made for the effects of age and sex so that the model tested the effect 
of the SNP if everyone in the cohort was the same age and sex.  Tests for interaction 
between BMP4 SNPs and previously associated SNPs in ARMS2/HTRA1, RORA, and 
ROBO1 were performed by adding an interaction term into the regression model.  
Additionally, a cases-only interaction analysis was performed using regression.  SNPs 
showing association at p≤0.2 in any cohort were tested for interaction with SNPs from 
genes in the RORA-ROBO1-HTRA1 pathway that included BMP4.   
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Results 
Of the first 4 SNPs genotyped, one SNP, rs12898159, showed significant 
association with both “all AMD subtypes” and neovascular AMD in the subset of the 
NESC cohort (p = 0.0084 and 0.0142, respectively; Table 1a).  No BMP4 SNPs showed 
significance in the Greek cohort (Table 1b).   Analysis of all the SNPs in the four cohorts 
did not show any SNPs significant among all cohorts (Tables 2-4).  Additionally, the two 
methods of analysis in the family cohorts (GEE and CLR) did not show consistent 
results, i.e., rs12898159 was shown to be highly significant in neovascular vs. normal in 
the NESC by GEE (p = 0.00E-00) but was not significant by CLR (p = 0.1401).  The 
complete results from all analyses can be found in Appendix A. 
The most significant SNP in the NESC was rs12898159 by GEE, which was 
shown to increase risk of neovascular AMD under an additive model (p = 0.00E-00), and 
rs17563 by CLR, which was shown to increase risk of all AMD subtypes under a 
recessive model (p =.01).  The most significant SNP in the Greeks was rs2761884, which 
was shown to be protective against neovascular AMD under a recessive genetic model   
(p = 0.03).  The most significant SNP in the GSSibs by GEE was rs4898820, which was 
shown to decrease risk of all AMD subtypes under a dominant model (p = 0.03), and the 
CLR analysis showed no significant associations for this cohort.  In the Korean cohort, 
the most significant SNP was rs17563, which was shown to increase risk of dry AMD 
under a recessive model (p = 0.0097). 
Combining all cohorts, and using the cases-only interaction analysis, a more 
powerful measure of interaction, significant interaction was seen between the BMP4 SNP 
rs17563 and SNPs in both ROBO1 and RORA.  Specifically, after correction for multiple 
  
 















rs2761880  A  0.333  0.035  3.205  0.3414  0.333  0.035  3.205  0.3414 
rs2761884  T  0.646  0.379  1.102  0.1092  0.685  0.408  1.151  0.1529 
rs2855529  T  0.686  0.402  1.171  0.1671  0.726  0.431  1.222  0.2284 


















rs2761880  A  0.796  0.428  1.483  0.4726  0.987  0.587  1.660  0.9600 
rs2761884  T  0.872  0.636  1.195  0.3941  0.954  0.722  1.260  0.7401 
rs2855529  T  0.875  0.637  1.203  0.4116  0.953  0.721  1.260  0.7353 
rs12898159  A  1.201  0.874  1.65  0.2592  1.034  0.779  1.372  0.8162 
 









study Comparison* Odds ratio Lower limit Upper limit Z-Value p-Value 
  Greeks AllAMD rs1884dom 1.147 0.775 1.698 0.685 0.4931
  NESC AllAMD (CLR) rs1884dom 0.293 0.089 0.965 -2.018 0.0436
Fixed       1.004 0.692 1.457 0.021 0.9836
  Greeks AllAMD rs7563add 1.063 0.802 1.408 0.426 0.6705
  Koreans AllAMD rs7563add 1.098 0.909 1.326 0.971 0.3317
  GSSibs AllAMD (CLR) rs7563add 0.644 0.192 2.161 -0.713 0.4761
  NESC AllAMD (CLR) rs7563add 1.704 1.037 2.801 2.103 0.0355
Fixed       1.123 0.968 1.302 1.528 0.1266
  Greeks AllAMD rs7563rec 0.978 0.626 1.527 -0.098 0.9221
  Koreans AllAMD rs7563rec 1.113 0.88 1.408 0.892 0.3726
  GSSibs AllAMD (CLR) rs7563rec 0.438 0.05 3.82 -0.747 0.455
  NESC AllAMD (CLR) rs7563rec 2.762 1.207 6.319 2.406 0.0161
Fixed       1.135 0.928 1.387 1.232 0.2178
  Greeks AllAMD rs8820dom 1.104 0.708 1.721 0.437 0.6624
  Koreans AllAMD rs8820dom 1.148 0.89 1.481 1.062 0.288
  GSSibs AllAMD (GEE) rs8820dom 0.335 0.118 0.947 -2.063 0.0391
  NESC AllAMD (GEE) rs8820dom 0.929 0.643 1.341 -0.394 0.6936
Fixed       1.038 0.862 1.25 0.391 0.6958
* Results of meta-analysis were conducted under three different genetic models (additive, dominant, and recessive) for all AMD 









study Comparison* Odds ratio Lower limit Upper limit Z-Value p-Value 
  Greeks NeoNorm rs8159add 1.171 0.848 1.618 0.958 0.3382
  GSSibs NeoNorm (GEE) rs8159add 0.996 0.532 1.866 -0.011 0.991
  NESC NeoNorm (GEE) rs8159add 2.488 2.144 2.886 12.036 0
Fixed       2.107 1.847 2.404 11.081 0
  Greeks NeoNorm rs8159dom 1.219 0.748 1.987 0.795 0.4269
  GSSibs NeoNorm (GEE) rs8159dom 0.963 0.432 2.151 -0.091 0.9277
  NESC NeoNorm (GEE) rs8159dom 1.686 1.036 2.744 2.102 0.0355
Fixed       1.348 0.982 1.851 1.848 0.0646
  Greeks NeoNorm rs8159rec 1.241 0.708 2.175 0.754 0.4506
  GSSibs NeoNorm (GEE) rs8159rec 1.069 0.26 4.4 0.093 0.9259
  NESC NeoNorm (GEE) rs8159rec 2.053 1.035 4.071 2.059 0.0395
Fixed       1.474 0.973 2.232 1.833 0.0669
  Greeks NeoNorm rs8820add 0.903 0.667 1.223 -0.659 0.51
  Koreans NeoNorm rs8820add 0.922 0.761 1.117 -0.831 0.4057
  GSSibs NeoNorm (GEE) rs8820add 0.654 0.347 1.232 -1.315 0.1886
  NESC NeoNorm (GEE) rs8820add 1.623 1.127 2.337 2.605 0.0092
Fixed       0.985 0.853 1.137 -0.208 0.8351
  Greeks NeoNorm rs8820dom 1.012 0.612 1.673 0.046 0.9629
  Koreans NeoNorm rs8820dom 1.14 0.845 1.537 0.859 0.3906
  GSSibs NeoNorm (GEE) rs8820dom 0.335 0.118 0.947 -2.063 0.0391
  NESC NeoNorm (GEE) rs8820dom 1.944 1.042 3.625 2.091 0.0366
Fixed       1.126 0.893 1.42 1.004 0.3153
* Results of meta-analysis were conducted under three different genetic models (additive, dominant, and recessive) for neovascular 
AMD, after adjustment for age and sex.  Only the significant analyses are presented (colored in pink). 
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study Comparison* Odds ratio Lower limit Upper limit Z-Value p-Value 
  Greeks NeoNorm rs1884dom 1.05 0.672 1.64 0.214 0.8303
  NESC NeoNorm (CLR) rs1884dom 0.195 0.046 0.822 -2.227 0.0259
Fixed       0.906 0.592 1.387 -0.455 0.6491
  Greeks NeoNorm rs1884rec 0.465 0.23 0.94 -2.132 0.033
  NESC NeoNorm (CLR) rs1884rec 1.199 0.379 3.794 0.309 0.7575
Fixed       0.602 0.33 1.097 -1.658 0.0973
  Greeks NeoNorm rs8820rec 0.748 0.45 1.243 -1.121 0.2623
  Koreans NeoNorm rs8820rec 0.645 0.452 0.92 -2.419 0.0156
  GSSibs NeoNorm (CLR) rs8820rec 2.329 0.275 19.741 0.775 0.4382
  NESC NeoNorm (CLR) rs8820rec 0.824 0.378 1.795 -0.487 0.6261
Fixed       0.707 0.54 0.927 -2.51 0.0121
  Greeks NeoNorm rs1884rec 0.465 0.23 0.94 -2.132 0.033
  NESC NeoNorm (GEE) rs1884rec 1.195 0.667 2.14 0.599 0.5493
Fixed       0.814 0.52 1.275 -0.898 0.3691
* Results of meta-analysis were conducted under three different genetic models (additive, dominant, and recessive) for neovascular 















study Comparison* Odds ratio Lower limit Upper limit Z-Value p-Value 
  Greeks NeoNorm rs8820rec 0.748 0.45 1.243 -1.121 0.2623
  Koreans NeoNorm rs8820rec 0.645 0.452 0.92 -2.419 0.0156
  GSSibs NeoNorm (GEE) rs8820rec 0.95 0.34 2.652 -0.098 0.9218
  NESC NeoNorm (GEE) rs8820rec 2.308 1.16 4.592 2.383 0.0172
Fixed       0.824 0.636 1.068 -1.465 0.143
  Greeks NeoNorm rs8820rec 0.748 0.45 1.243 -1.121 0.2623
  Koreans NeoNorm rs8820rec 0.645 0.452 0.92 -2.419 0.0156
  GSSibs NeoNorm (GEE) rs8820rec 0.95 0.34 2.652 -0.098 0.9218
  NESC NeoNorm (GEE) rs8820rec 2.308 1.16 4.592 2.383 0.0172
Fixed       0.824 0.636 1.068 -1.465 0.143
* Results of meta-analysis were conducted under three different genetic models (additive, dominant, and recessive) for neovascular 









within study Comparison* Odds ratio Lower limit Upper limit Z-Value p-Value 
  Greeks DryNorm rs7563add 0.959 0.637 1.445 -0.2 0.8413
  Koreans DryNorm rs7563add 1.46 1.073 1.987 2.408 0.0161
  NESC DryNorm (CLR) rs7563add 4.204 0.668 26.452 1.53 0.126
Fixed       1.281 1.004 1.636 1.991 0.0464
  Greeks DryNorm rs7563dom 1.286 0.648 2.553 0.719 0.4721
  Koreans DryNorm rs7563dom 1.394 0.64 3.037 0.836 0.403
  NESC DryNorm (CLR) rs7563dom 0.956 0.134 6.827 -0.045 0.9642
Fixed       1.304 0.793 2.145 1.045 0.2959
  Greeks DryNorm rs7563rec 0.688 0.34 1.392 -1.04 0.2983
  Koreans DryNorm rs7563rec 1.631 1.126 2.363 2.585 0.0097
Fixed       1.353 0.974 1.878 1.804 0.0713
  Greeks DryNorm rs7563add 0.959 0.637 1.445 -0.2 0.8413
  Koreans DryNorm rs7563add 1.46 1.073 1.987 2.408 0.0161
  NESC DryNorm (GEE) rs7563add 1.082 0.779 1.503 0.47 0.6385
Fixed       1.189 0.977 1.449 1.726 0.0844
  Greeks DryNorm rs7563rec 0.688 0.34 1.392 -1.04 0.2983
  Koreans DryNorm rs7563rec 1.631 1.126 2.363 2.585 0.0097
  NESC DryNorm (GEE) rs7563rec 0.989 0.549 1.781 -0.037 0.9705
Fixed       1.256 0.943 1.672 1.557 0.1194
* Results of meta-analysis were conducted under three different genetic models (additive, dominant, and recessive) for dry AMD, 
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testing, significant interactions were seen between BMP4 rs17563 and RORA SNPs 
rs730754 and rs8034864 and ROBO1 rs4513416 and rs1387665 (Table 5).  The most 
significant interaction was between BMP4 rs17563 and RORA rs8034864 among dry 
AMD cases only (p = 9.78E-09). 
 
Discussion 
Considering these results specifically in regards to the association between BMP4 
and AMD, this research has added important information to the general understanding of 
the underlying genetic mechanisms and interactions associated with this disease.  One 
thing is abundantly clear: AMD is a complex and complicated disease in which risk 
factors and genetic interactions differ between populations, disease types, and 
combinations of the two.  The research presented here supports the placement of the 
BMP4 gene within the RORA-ROBO1-HTRA1 network, as it is clearly functioning 
within this network as an independent risk factor for and protectorate against AMD.  
Moreover, SNPs within the BMP4 gene are interacting with a few specific SNPs within 
the RORA and ROBO1 genes to independently increase the risk of both dry and wet 
AMD in different situations.  Not surprisingly, the BMP4 SNP rs17563 which has been 
tied to OPLL (Meng et al., 2010; Ren et al., 2012a) appears to be a key factor in relation 
to the disease; it independently increases risk for all AMD subtypes, and dry AMD 
specifically, among the NESC cohort and Korean cohort, respectively.  In addition, this 
SNP is associated with the most significant interaction among genetic risk factors in both 
neovascular and dry AMD cases. 
In looking at BMP4’s direct relation to AMD, it is slightly discouraging that
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BMP4 rs12898159  0.832  0.658  1.052  0.124  0.714  0.538  0.948  0.0197  1.43  0.892  2.292  0.1372 
ROBO1 rs1387665 & 
BMP4 rs12898159  0.811  0.664  0.99  0.0395  0.741  0.585  0.939  0.0133  0.964  0.636  1.459  0.8614 
ROBO1 rs4513416 & 
BMP4 rs12898159  1.242  1.017  1.518  0.034  1.409  1.11  1.789  0.0048  1.01  0.665  1.533  0.9634 
ARMS2 rs10490924 
& BMP4 rs17563  1.197  1.028  1.393  0.0206  1.18  0.978  1.424  0.0838  1.252  0.938  1.67  0.1268 
HTRA1 rs11200638 & 
BMP4 rs17563  1.275  1.097  1.483  0.0016  1.211  1.007  1.456  0.0422  1.417  1.06  1.894  0.0186 
HTRA1 rs1049331 & 
BMP4 rs17563  1.246  1.073  1.446  0.004  1.183  0.984  1.422  0.0734  1.37  1.028  1.824  0.0314 
RORA rs730754 & 
BMP4 rs17563  1.32  1.136  1.533  0.0003  1.163  0.967  1.398  0.1086  1.928  1.432  2.596  1.51E‐05 
RORA rs12900948 & 
BMP4 rs17563  1.156  0.995  1.344  0.0582  1.095  0.909  1.32  0.3389  1.343  1.004  1.797  0.0467 
RORA rs8034864 & 
BMP4 rs17563  1.474  1.27  1.711  3.47E‐07  1.267  1.055  1.522  0.0114  2.438  1.798  3.307  9.78E‐09 
ROBO1 rs1387665 & 
BMP4 rs17563  0.76  0.653  0.885  0.0004  0.71  0.591  0.853  0.0003  0.853  0.627  1.16  0.3098 
ROBO1 rs4513416 & 
BMP4 rs17563  1.268  1.089  1.477  0.0023  1.399  1.161  1.687  0.0004  1.096  0.813  1.478  0.5455 
* Summary of significant cases-only interaction analysis between the BMP4 SNPs and SNPs from the RORA-ROBO1-HTRA1 
triumvirate among all cases and wet (Neo) and dry cases specifically (significant interactions are in pink).
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consistent results between the two statistical methods were unobtainable when 
significance was seen in one method.  Regardless, the results tell us a number of things 
about the gene in relation to this disease.  In looking just at the most significant SNPs in 
each of the cohorts, it appears that SNPs at and around LD Block 1 (Figure 5) increase 
the risk of AMD in all subtypes, while SNPs at and around LD Block 2 are protective 
against neovascular AMD or reduce the risk of all subtypes of AMD.  Each cohort was 
associated with a different most significant SNP, and only rs17563 was at a significant 
level in multiple cohorts (NESC and Koreans).  This reaffirms the concept that AMD 
may have different genetic risk factors in different populations.  Interestingly, in addition 
to rs17563 which has already been discussed as a risk factor in other diseases, the most 
significant SNP in the GSSibs cohort, rs4898820, which decreased the risk of all AMD 
subtypes, has been implicated in the pathogenesis of adolescent idiopathic scoliosis (AIS) 
(Mórocz et a., 2011).  This is an excellent example of the importance of understanding 
the multiple roles SNPs play in different diseases and in personalized medicine.  If 
clinicians attempted to target this SNP as a treatment for AIS without understanding its 
protective benefits for AMD or the individual patient’s overall risk of developing AMD, 
they might inadvertently increase the patient’s susceptibility to one disease while trying 
to treat another.  While many drugs and other treatments have side effects, it is important 
to balance the risks with the benefits, especially in regards to the disruption of vital 
functions, such as sight. 
In the cases-only interaction analysis there were a number of interesting results.  
The BMP4 SNP rs17563 was associated with all four of the most significant interactions, 
two with SNPs in the RORA gene and two with SNPs in the ROBO1 gene.  The two 
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most significant interactions were between BMP4 and RORA (rs730754, p = 1.51e-5 and 
rs8034864, p = 9.78e-9), and both interactions increased the risk of dry AMD.  In 
contrast, both of the highly significant BMP4-ROBO1 interactions, rs4513416 and 
rs1387665, are associated with an increased risk of wet AMD (p = 0.0004 and p = 
0.0003, respectively).  These differences in risk factors between subtypes was seen 
throughout the analysis with six interactions only significant (or considerably more 
significant) in wet cases, and seven interactions only significant (or considerably more 
significant) in dry cases (Table 5).  The only significant interaction that involved the 
HTRA1 gene (rs1049331) also involved the BMP4 SNP rs17563, and was only 
significant among cases of dry AMD.  Variants within the BMP4 gene are clearly 
involved in all aspects of AMD pathogenesis and specific variants may be utilized as 
therapeutic targets for the specific subtypes of AMD. 
 These results may be highly informative in better understanding the genetic 
mechanisms behind the pathogenesis of AMD and the utility of BMP4 as a therapeutic 
target, and at first glance the results may also suggest the utility of the rs17563 SNP in 
the proposed OPLL-BMP4-AMD identification method, however, there is more to 
consider than just the surface results.  The specific parameters of the hypothesis along 
with the details of the results and the various aspects of the analysis combine to form a 
much more complex picture.  Issues such as study cohort, significance level, 
repeatability, and disease subtype influence how these results should be interpreted in 
relation to the practicality of the proposed identification methods.  All these factors, 
along with the OPLL results presented in the next chapter will be discussed in relation to 
the proposed method in the OPLL-BMP4-AMD Identification Method section. 
         
 
OSSIFICATION OF THE POSTERIOR LONGITUDINAL LIGAMENT 
 
Introduction 
The second important aspect of this research concerns ossification of the posterior 
longitudinal ligament (OPLL) in the cervical spine.  The posterior longitudinal ligament 
runs along the back of the vertebral body, in the spinal column, from the second cervical 
vertebra (C2) in the neck to the sacrum of the pelvis, and is adherent to and sometimes 
blends with the hard outer covering of the intervertebral discs (Taguchi, 2006).  
Ossification, or the change of the ligament into bone, causes the ligament to expand 
beyond the normal anatomical bounds, where it firmly attaches to the vertebral bodies 
and discs (Epstein, 2002a).  Ossification can impinge on the spinal cord causing a number 
of neurological problems (Singh et al., 2004).  Diagnosis occurs via radiographs taken at 
clinics when patients suffering from neck pain come in seeking treatment (Figure 6).  
OPLL has been a disease of significant interest in Japan for the last 40 years.  As 
a result, until about five to six years ago, most of the literature on the disease was coming 
out of Asia, with a few sporadic reports from other countries.  For a majority of this time 
period OPLL was considered to be a “Japanese Disease,” as it was believed to reach its 
highest prevalence in this population (Matsunaga and Sakou, 2006a).  Other Asian 
populations are thought to present with the next highest prevalence.  However, OPLL 




Figure 6. A classic radiographic example of OPLL. Image as seen in a clinical setting. 
 
Japanese.  Historically, OPLL is considered to be mostly anecdotal among European 
populations, with a suspected prevalence of 1.7% (Harsh et al., 1987; Koga et al., 1998; 
Saetia et al., 2011).  More recently, investigators report that due to OPLL’s association 
with other common bone diseases in Whites, the disease must have a higher incidence in 
the population than was previously thought, and similar demographic attributes as among 
Asians (Matsunaga and Sakou, 2006b; Kalb et al., 2011; Wang and Thambuswamy, 
2011; Wu et al., 2011).  Although, the overall prevalence is considered to be similar to 
that proposed by Koga and colleagues in 1998 (up to 1.7%).  
 The fact that OPLL is believed to be a rare disease among individuals with 
European ancestry, and most populations outside of Asia, makes it an ideal candidate for 
a forensic identification methodology.  A rare skeletal manifestation such as OPLL has 
the potential of narrowing down possible matches in a candidate pool when trying to 
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identify remains.  For the sake of this research, the proposed scarcity of OPLL among 
populations provides the tool for reducing candidates and improving matches, while the 
OPLL-BMP4-AMD connection provides the database from which to draw potential 
matches.  This chapter will discuss the aspects of OPLL, the history of research 
concerning the disease, and present the results of the research conducted for this project 
to better understand the true prevalence of OPLL outside Asian populations. 
 
Explanation of the Disease and History of Research 
 Interest in OPLL, especially ossification in the cervical spine, has a surprisingly 
long history.  In 1838 CA Key reported that ossification of the spinal ligaments could be 
responsible for spinal cord paralysis and subsequent paraplegia (Matsunaga and Sakou, 
2006a).  The disease attracted further attention in 1960 when Tsukimoto presented a post-
mortem case report where severe spinal cord symptoms were caused by ossification 
within the ligaments of the cervical spinal canal (Tsukimoto, 1960).  Originally, the 
disease was termed “calcification of the posterior longitudinal ligament.”  However, after 
a pathology study a few years later showed that this condition involves true ossified 
tissue, “ossification of the posterior longitudinal ligament” was proposed as a name-
change, and the disease has been known as OPLL ever since (Terayama et al., 1964). 
 Ossification of the cervical posterior longitudinal ligament represents a continuum 
of disease beginning with hypertrophy of the posterior longitudinal ligament (PLL) 
(Figure 7) followed by progressive coalescence of centers of chondrification and 
ossification (Bizri et al., 2009).  The PLL is composed of two strata of fibers and runs 




Figure 7. Location of the spinal ligaments. The PLL (purple) runs the length of the spinal 
column, and while this paper discusses the cervical spine, the spinal ligaments are show 
here in the thoracic region for clarity (From Wikimedia Commons). 
 
 
intervertebral discs than to the vertebral bodies themselves, which is why in some cases 
OPLL seems to hover just over the vertebra (Figure 6).  The PLL significantly differs 
from the anterior longitudinal ligament in the clinical sense as any alteration in the 
anatomy of the PLL can have severely negative effects on the spinal cord and nerve roots 
(Taguchi, 2006).  The initial hypertrophy of the PLL which leads to ossification is 
attributed to fibroblastic hyperplasia and increased collagen deposition.  This is followed 
by progressive mineralization and cartilaginous growth resulting in immature ossification 
centers, which later mature into Haversian canals, which are actively engaged in bone 
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marrow production (Epstein, 2002c).  In addition to the work done by Terayama et al. 
(1964) into the pathology of the ossification, other research has confirmed the fact that 
OPLL is composed of osseous tissue derived from endochondral bone formation 
(Tsuzuki, 2006; Saetia et al., 2011).  
Growth of the ossification averages 0.4 mm/yr in depth, and 0.67 mm/year in 
length (Epstein, 2002c).  Although a high number of cases present asymptomatically, 
symptoms include sensory and motor dysfunction, abnormal reflexes, general problems 
with the nerves and spinal cord, and even neurological dysfunction (Epstein, 2002c; 
Chang et al., 2012).  The most commonly reported symptom is myelopathy or pathology 
related to the spinal cord resulting from compression, which is of note as OPLL is often 
overlooked as an independent cause of myelopathic conditions (Hirabayashi et al., 1981; 
Harsh et al., 1987; Singh et al., 2004; Taguchi, 2006; Hsieh and Wang, 2011; Saetia et 
al., 2011).  The average age of onset for the disease is around the 50 years, with the 
highest prevalence in the sixth decade of life (Nose et al., 1987; Kaneko, 2006; 
Kawaguchi et al., 2006; Matsunaga and Sakou, 2006b).   Twice as many males present 
with the disease as females (Koga et al., 1998; Singh et al., 2004; Matsunaga and Sakou, 
2006a; Wu et al., 2011; Jeon et al., 2012).  About 70% of cases are localized to the 
cervical vertebrae, with the rest equally distributed throughout the thoracic and lumbar 
spines (Trojan et al., 1992; Epstein et al., 2002c; Stapleton et al., 2011).  In effect, OPLL 
of the cervical spine is the primary research target for most investigators in the field.  
Four distinct types of OPLL were characterized and defined by Hirabayashi et al. (1981) 
and have become the standard for research.  The four types (Figure 8) are continuous 








The segmental type consists of one or more separate lesions behind the vertebral bodies, 
the continuous type is a long lesion extending over several bodies, the mixed type is a 
combination of segmental and continuous lesions, and the other type consists of lesions 
mainly posterior to the disc space (Hirabayashi et al., 1981; Nagata and Sato, 2006).  The 
continuous type has been repeatedly seen as occurring most frequently at the levels C2-
C4. 
OPLL has been extensively studied in Asian populations with a proposed 
prevalence of up to 4.3% in Japanese, and more recently, a potential prevalence of up to 
8.92% among Chinese (Ren, 2012a).  Understanding the disease is of profound 
importance in Japan, and there are a number of committees dedicated solely to the 
improvement in practical and clinical knowledge of the disease (Nakamura, 2006).  
Consequently, the most informative literature is coming from this part of the world, 
although now there is a push to consider this disease as a possibility in every population.   
While there does appear to be a conscious move away from the notion that OPLL is a 
“Japanese disease,” there is still little known about the specifics of the disease in non-
Asian populations: although a peak prevalence of 1.7% has been reported in Whites 
(Koga et al., 1998).  Harsh et al. (1987) reported that OPLL in his time was rare in North 
America, citing only 20 patients in the literature.  A few years later, Trojan et al. (1992) 
claimed there were no incongruities between the presentation of the disease among 
Japanese and non-Japanese, based solely on eight case studies.   But recently, Kalb et al. 
(2011) and a number of other researchers have tried to instill the idea that there is a 
higher prevalence of OPLL in European and North American populations than was ever 
previously considered (Wang and Thambuswamy, 2011).  Today, there are a number of 
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institutions that treat OPLL in the United States, such as the Mayo Clinic, The Spine 
Institute in Los Angles, Irvine Orthopedic Associates of California, and a number of 
neurosurgery departments in institutions like the University of Utah.  However, as OPLL 
is still not considered a prominent problem in the U.S., these clinics only treat on a case 
by case basis and do not report OPLL as a specialty.  This fact suggests that while there is 
belief that OPLL prevalence in American populations is higher than the historically 
reported 1.7%, it is still rare enough to be useful for an identification method.  Also, the 
interest in finding the true prevalence of OPLL in non-Asian populations makes the 
research undertaken for this project, and discussed below, pertinent not only to the 
forensic or anthropological communities, but to the medical community as well.  
 
Etiology and Genetics 
In spite of the long history of interest and research concerning this disease, the 
etiology of OPLL still remains unclear.  Some suggested theories include an infectious 
etiology, fluoride intoxication, an immunological mechanism, diabetes mellitus, and even 
trauma, although none has gained acceptance (Singh et al., 2004; Jones et al., 2011; 
Chang et al., 2012).  The concept of trauma-induced induction of OPLL has been a 
favorite theory with many researchers.  However, studies have show that trauma or 
repeated mechanical stress, especially in the cervical spine, only serves to progress 
already existing OPLL or cause myelopathy in individuals already suffering from OPLL 
(Tanno et al., 2003; Jones et al., 2011; Chang et al., 2012).  There is an understanding 
that the pathogenesis of OPLL is a complicated mixture of many genetic and 
environmental aspects, that as of yet, remain unclear (Karasurgi et al., 2013). 
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In contrast to the work done on the possible environmental factors of OPLL, 
research into the genetic factors which influence OPLL has been much more informative.  
There is a strong familial link to the disease, with 20-30% of relatives also having the 
disease, and 85% of monozygotic twins also having OPLL (Matsunaga and Sakou, 
2006a; Stetler et al., 2011).  In terms of genetic risk factors, a number of genes in the 
BMP family have been reported to have abnormal expression in relation to this disease 
(Stetler et al., 2011).  Specifically, studies on BMP2, BMP4, and BMP9 have shown that 
these genes are localized near sites of ossification and contain SNPs which increase the 
risk of developing OPLL (Furushima et al., 2002; Hoshi, 2006; Wang et al., 2008; Meng 
et al., 2010; Ren et al., 2012a,b; Yan et al., 2013).  The BMP4 gene, which was the 
inspiration for this research, has been long thought to have a significant part in the onset 
and extent of OPLL (Furushima et al., 2002; Tanaka et al., 2003; Yoshikawa, 2006).  A 
study by Meng et al. (2010) concluded that male Chinese Han patients with the CT and 
TT genotypes at SNP rs17563 within BMP4 have a greater susceptibility to OPLL and 
have more extensive OPLL in the cervical vertebra of the neck.  More recently, Ren et al. 
(2012a) looked at 18 SNPs within BMP4 and confirmed that rs17563 significantly 
increases susceptibility to OPLL in both males and females.   
Genetic studies of OPLL have also revealed several gene loci outside the BMP 
family that may be involved in the pathogenesis of this disease. Genes encoding for 
proteins that process extracellular inorganic phosphate, collagen fibrils, and transcription 
factors involved in osteoblast and chondrocyte development and differentiation have all 
been implicated in the pathophysiology of OPLL (Stapleton et al., 2011).  Genome-wide 
searches have identified chromosomes 1, 2, 6, 7, 11, 14, 16, 20, and 21 as possibly 
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housing genes which contribute to the susceptibility and progression of OPLL (Tanaka et 
al., 2003; Karasurgi et al., 2013).  Specific genetic factors that have already been targeted 
for research and clarification include the Vitamin D receptor, Types VI and XI collagen 
receptors, the alpha B crystalline receptor, and the HLA complex (Koga et al., 1998; 
Bizri et al., 2009; Stapleton et al., 2011; Stetler et al., 2011).  Research has also been 
conducted on the genes CDH13, COL6A1, COL11A2, IGF1, NPP1, OPN, PRG1, 
PTHR1, and TGFβ3, although none of these genes is thought to match the influence of 
BMP4 (Koga et al., 1998; Furushima et al., 2002; Tanaka et al., 2003; Stapleton et al., 
2011). 
Genetic research into the etiology of OPLL has also focused a great deal on the 
relationship between OPLL and two other ligament problems local to the spine.  During 
the earliest research into OPLL, it was thought that this disease was a subtype of the 
condition known as diffuse idiopathic skeletal hyperostosis (DISH; Matsunaga and 
Sakou, 2006b).  DISH is a syndrome which involves ossification of the soft tissue and 
ligaments near the ventral aspect of the cervical and/or thoracic spine (Mader, 2002).  For 
anthropologists, the hallmark of DISH is the wax-like ossification that flows down the 
right anterior portion of the vertebral bodies.  Today OPLL is considered to be its own 
disease, but it is reported to occur in about 50% of DISH cases, suggesting there must be 
a genetic link which induces ossification (Trojan et al., 1992; Koga et al., 1998; Saetia et 
al., 2011).  The second disease of interest for OPLL researchers is ossification of the 
ligamentum flavum (OLF).  OLF is a disease of ectopic bone formation within the 
ligamentum flavum (Figure 7), which may result in neurological compromise much like 
OPLL (Christiano et al., 2011).  OLF is thought to mimic OPLL in that it has a high 
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prevalence among the Japanese and it has a male preponderance.  OLF and OPLL are 
often discussed together because they both reside within the spinal canal, ossification of 
one is often associated with ossification of the other (suggesting a possible genetic link), 
and most importantly, any treatment must consider the effect on both ligaments (Iwasaki, 
2006; Yoshida, 2006; Kotani et al., 2013).  Thus, while OPLL is an independent disease, 
there are clearly strong genetic associations between the various intraligament 
ossification disorders of the spine. 
 
Diagnosis and Treatment 
 Due to the nature of OPLL, all current clinical diagnoses are performed 
radiographically.  Traditionally, plain radiographs and lateral or transverse x-rays were 
the preferred method of diagnosis (Koga et al., 1998; Yonenobu et al., 2006; Chang et al., 
2012; Jeon et al., 2012).  Today a number of other techniques are used in addition to the 
traditional methods, including CTs, MRIs, and diffusion tensor imaging which is believed 
to provide more information to clinicians when preparing surgical options (Tanaka et al., 
2006; Jones et al., 2011).  One aspect of diagnosis that has not changed over the years is 
the fact that radiographs are only taken when a patient comes in complaining of neck pain 
or presents with a number of the neurological and nerve symptoms associated with the 
disease.  This fact is very important to the research described here as this method of 
diagnosis precludes the identification of earlier stage or minimal ossification that may not 
cause any problems, and excludes individuals who are asymptomatic and never have 
cause to seek treatment from the prevalence reports.  Prevalence studies resulting from 
such diagnostic criteria have the drawback of representing only those actively suffering 
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from the disease, instead of all the individuals in the population who have OPLL, 
regardless of clinical presentation. 
 Treatment for OPLL is a sensitive and often challenging issue because of the 
ossification’s location in an enclosed space and its proximity to the spinal cord.  Since 
surgical treatment was first attempted in this area, there has been a great deal of 
discussion as to what form of surgery is best for what case, when in a person’s life it 
should be performed, at what extent of ossification surgery is necessary, and how long 
the treatment can be expected to last (Epstein, 2001; Cardoso et al., 2011; Vedantam et 
al., 2011; Wu et al., 2012).  Currently, there are two anterior and two posterior surgical 
approaches that have gained general acceptance in the clinical community (Epstein, 
2002a,b).  Unfortunately, neither approach has been overly successful and there are a 
number of complications that arise after surgery, including spinal cord injuries, general 
disability, and postoperative progression of the ossification (Ngata and Sato, 2006; Wu et 
al., 2011; Wu et al., 2012).  Once again, there is an aspect of this disease which is 
discouraging in the clinical sense but promising in terms of the proposed identification 
method.  Since surgical treatment of OPLL is often ineffective, it means that OPLL 
should be visible in the population at every stage of its development and throughout the 
foreseeable future, making it an identification target that could be used for some time. 
 
Comparative Skeletal Analysis 
Introduction 
 The second aspect of the research undertaken was the analysis of OPLL in an 
American skeletal population.  Historically, interest in this disease has been centered in 
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Asia, especially in Japan, and little research as been done into the specifics of the disease 
among other populations, except for the few incidences discussed above.  In addition, 
diagnosis of this disease is traditionally based on radiographic analysis of clinical patients 
complaining of spinal and/or neurological symptoms.  As a result, diagnosis often occurs 
only in symptomatic individuals, and only after the disease has reached an extreme state.  
In order to better understand the prevalence of OPLL among American populations, how 
the presentation of the disease differs between radiographic and skeletal diagnosis, and 
the utility of this disease as an identification method in forensics, a sample of 1051 50+ 
year old White and Black males and females were analyzed from the Smithsonian’s Terry 
Collection.  The Terry Collection is currently comprised of approximately 1728 complete 
skeletons of individuals of known sex, age, ancestry, cause of death, and pathological 
conditions, spanning in age from 16-102 years who died during the 20th century (Hunt 
and Albanese, 2005).  Individuals with missing or questionable demographic information 
were not used in this study. 
 
Methods 
 The study population was composed of individuals 50 years and older because the 
average age of onset of the disease is around 50 years, and the highest prevalence of the 
disease is thought to occur in the sixth decade of life (Nose et al., 1987; Koga et al., 1998; 
Kaneko, 2006; Kawaguchi et al., 2006; Matsunaga and Sakou, 2006b).  In addition, the 
cervical spine was specifically targeted for this study since 70% of OPLL cases occur in 
this location, and much of the specific research into this disease, including the genetic 
association of BMP4, has been linked directly to OPLL of the cervical spine (Trojan et 
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al., 1992; Tanaka et al., 2003; Nagata and Sato, 2006; Meng et al., 2010).  Thus, the study 
population consisted of all cases in the Terry collection which were identified as 50 or 
older and had a complete cervical spine (C-spine).  A list of all pertinent case numbers 
was compiled and to avoid bias in the initial analysis, defining features in the case record, 
such as sex, age, and ancestry, were blocked out until after all the cases were examined.  
A total of 1060 cases were available for analysis according to the records.  An initial 
examination of the collection identified six cases where the C-spine was missing or 
incomplete and three cases where the individual was actually of Asian ancestry, leaving 
1051 Black and White individuals with well preserved C-spines for analysis. 
 For each case, the entire cervical spine was examined for the presence of OPLL.  




Figure 9. Terry Collection vertebra with no ossification. The red arrow points to the flat 
surface of the vertebral body. View is posterior-inferior. 
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set aside.  Only if ossification was present, even on just one vertebra, was further 
information collected and additional analysis conducted.  OPLL was considered present if 
the telltale ossification on the back of the vertebra was visible or palpable, at which point 
information was taken on the type, location, and extent of the ossification (see Appendix 
B).  Identification through palpation was shown to be sensitive down to a 10th of a 
millimeter in thickness.  Measurements were taken to the nearest 100th of a millimeter 
with a digital caliper at the maximum length, width, and depth of ossification (Figure 10).  
Photographs were taken throughout the analysis to exemplify the variability of the 
presentation of OPLL throughout the collection and between the various subgroups of 
















 After all the prevalence data, measurements, and photographs were completed, 
the sex, age, and ancestry for each case was revealed and cases were grouped by sex, age, 
ancestry, and sex/ancestry for analysis.  Both qualitative and quantitative assessments 
were carried out on the data.  Statistical tests were conducted using the statistical package 
R version 2.15.1 (2012-06-22) to identify differences in prevalence and extent of 
ossification by group.  Results were then compared to previously accepted aspects of the 
disease to note any differences or deviations from currently accepted demographics of 
OPLL among populations.  
 
Results 
 Prevalence.  The overall prevalence in the study population was much higher than 
anything previously reported on either Asian or non-Asian populations.  Of the 1051 
individuals studied, 542 presented with OPLL for an overall collection prevalence of 
52%.  In the various subpopulation groups in the study, there were likewise interesting, 
and highly unexpected results ranging from 32-67% prevalence (Figure 12).  Ossification 
occurred in 299 of 617 cases (48%) in Whites, 244 of 435 cases (56%) in Blacks, 372 of 
587 cases (63%) in males, 171 of 464 (37%) in females, 213 of 351 cases (61%) in White 
males, 86 of 266 cases (32%) in White females, 159 of 237 cases (67%) in Black males, 
and 85 of 198 cases (43%) in Black females.  Among the specific age groups the 
prevalence was as follows: 55% in the 50s (N=324), 54% in the 60s (N=357), 48% in the 
70s (N=252), 47% in the 80s (N=105), 20% in the 90s (N=15), and 100% in the over 100 
group.  It should be mentioned that the 100+ group only consisted of two individuals, 




   




 Groups were compared for differences using Pearson’s Chi-Squared tests at the   
p = 0.05 level.  The prevalence among males is significantly higher than among females 
(p < 2.2x10-12), significantly higher among White males compared to White females        
(p = 2.98x10-12), and significantly higher among Black males compared to Black females 
(p = 4.28x10-7).  There is a significant difference between White and Black females         
(p = 0.0193) and between all Whites and all Blacks (p = 0.0147), but there was no 
significant difference between White and Black males.  When comparing all age groups 
there was a small difference between the groups (p = 0.028), but when the 90s and 100s 
were removed from the analysis for small sample size (only a total n=17), there was no 
apparent significant difference (p = 0.2021).  
 Type.  Three of the four types of OPLL were witnessed in the study population: 
segmental, continuous, and mixed (Figure 13); type “other” was not seen.  Almost all of 
the cases were segmental (98.90%) with two examples of continuous OPLL (0.37%) and 
four cases of mixed OPLL (0.73%).  The two continuous cases were White individuals, 
one male and one female.  The mixed cases included two Black males, one White male, 
and one Black female.  Statistics were not performed between groups with this aspect of 
the data due to the very small number of cases which were not of the segmental type.  
The results would have appeared significantly different because of the small sample, 
regardless of any actual significance. 
Location.  There were 32 different location combinations (Figure 14) in the 
population with the most common location being cervical vertebrae C3-4 (125 cases).  
The most common vertebrae involved were C3, C4, and C5, respectively.  Segmental 
cases occurred in all parts of the C-spine while the continuous type was found primarily
  
 








Figure 14. Location of ossification in the Terry Collection. Combinations seen on cervical vertebrae C2-C7. Black and grey coloring is 




in the upper half of the C-spine.  
 Extent. Most cases of OPLL involved ossification over 2-5 vertebral bodies, with 
the average being 3.2 vertebrae.  The area of ossification on the most ossified vertebra 
ranged from 3.53 to 255.35 cubic millimeters.  The average area of ossification on the 
most affected vertebral body for the major subpopulation groups ranged from 51 to 65 
mm3: 62.31 mm3 in Whites, 62.55 mm3 in Blacks, 65.69 mm3 in males, 55.33 mm3 in 
females, 66.75 mm3 in White males, 51.29 mm3 in White females, 64.24 mm3 in Black 
males, and 59.40 mm3 in Black females.  Mean area of the groups were compared by 
using a combination of the F-test to compare two variances and a two sample t-test to test 
for a true difference in means.  There was no significant difference in the mean area 
between Whites and Blacks, between White and Black females, White and Black males, 
or Black males and females.  There was a significant difference in area between all males 
and all females (p = 0.0125) and between White males and White females (p = 0.0067), 
suggesting that the majority of the male-female difference is coming from the 
discrepancy in the White population. 
 Among the age groups, the area of ossification was highest among those in their 
90s with an average of 84.97 mm3, followed by those individuals in their 70s, with an 
average ossification of 72.99 mm3.  When taken as an entire collection, there were no 
significant differences in mean ossification associated with age group.  
There is a wide range of ossification extent throughout the collection (Figure 15).  
Some cases presented with wide and relatively flat ossification, other cases presented as 
thin and deep, and there were cases that presented with every combination in between.  





Figure 15. Variation of ossification seen in the collection. Image A is an example of a 
White female with an overall small area of ossification that is primarily flat.  Image B is 




However, as can be expected by the statistical differences of ossified area between male 
and females, the females qualitatively seemed to present more frequently with the thinner 
and flatter ossification patterns.  
 
Discussion 
 The results from this research conducted on OPLL in White and Black 
populations strongly contradict what was previously understood about the prevalence of 
this disease in non-Asian populations.  The prevalence range witnessed (32 – 67%) brings 
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into question not only the past assumptions about American population OPLL 
prevalence, but also the prevalence of the disease in Asian groups as well.  One of the 
key differences is that this research was conducted on a skeletal collection, whereas 
OPLL is traditionally diagnosed through radiographs of patients seeking treatment for 
neck or neurological complaints.  Skeletal assessment of the disease allows for an 
understanding of the true number of potential sufferers in the population, whether or not 
they are currently symptomatic.  Ossification was recorded at a sensitivity of 0.10 mm, a 
depth that would be difficult to see on radiographs and most certainly not cause 
symptoms.  Thus, this study identified a wider range of OPLL cases than is currently seen 
by clinicians.  
 As a result of using a skeletal population for analysis and such a sensitive degree 
of identification of ossification, there is the concern that the high prevalence witnessed 
here is an artifact of an overabundance of early stage or minimal ossification.  Taking 
into account Epstein’s 1994 paper suggesting an early form of OPLL, which she termed 
“OPLL in evolution” (OEV), and the measurements of the spinal canal, a reassessment of 
the data was conducted to quell such concerns.  Research into the spinal column has 
shown that the average diameter of the normal spinal canal in the cervical spine is 13-15 
mm, and the diameter of the spinal cord can very greatly in this region, from 8.8 to 14 
mm (Sherman et al., 1990; Morishita et al., 2009).  Consequently, it was proposed for this 
follow-up analysis that any ossification less than 1 mm in depth would be considered an 
early stage, or OEV, and be taken out of the dataset.  The depth of 1 mm equates to at 
least 2.5 years of ossification growth and, according to the diameter of both the spinal 
cord and spinal canal, has the potential to impinge on the spinal cord causing adverse 
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reactions and classic OPLL symptoms (Epstein, 2002c). 
 In the modified dataset, there were a total of 769 individuals, 456 White and 313 
Black.  The same analyses were carried out in terms of prevalence to show that, even 
when removing OEV cases which would most likely never be seen by a clinician, the 
prevalence witnessed in these populations is much greater than has been reported or 
suspected anywhere in the world.  Overall, the modified collection population had an 
OPLL prevalence of 34%, down from the 52% seen when the OEV cases are added, but 
still much higher than the anticipated 1.7%.  Ossification occurred in 138 of 456 cases 
(30%) in Whites, 122 of 313 cases (39%) in Blacks, 187 of 403 cases (46%) in males, 73 
of 366 (20%) in females, 106 of 244 cases (43%) in White males, 32 of 212 cases (15%) 
in White females, 81 of 159 cases (51%) in Black males, and 41 of 154 cases (27%) in 
Black females.  Among the specific age groups the prevalence was as follows: 33% in the 
50s, 37% in the 60s, 33% in the 70s, 31% in the 80s, 14% in the 90s, and 100% in the 
over 100 group.  Again, the 100+ group only consists of 2 Black females with significant 
ossification, and should only be discussed anecdotally.  A comparison of the original 
cohort compared to the modified cohort and previously published results can be seen 
below (Figure 16).   
 Groups were once again compared for differences using Pearson’s Chi-Squared 
tests at the p = 0.05 level.  The prevalence among males is still significantly higher than 
among females (p < 3.78x10-8), significantly higher among White males compared to 
White females (p = 1.087x10-6), and significantly higher among Black males compared to 
Black females (p = 0.0033).  There is a significant difference between White and Black 
females (p = 0.02697), but there was no significant difference between White and Black 
  
 
Figure 16. OPLL prevalence in the collection with and without OEV cases. Comparison of the two study populations and the currently 




males (p = 0.3743), and no significant difference between all Whites and all Blacks         
(p = 0.07919).  Among the age groups, there was no significant difference between all the 
groups (p = 0.6344), and when the 90s and 100s were removed from the analysis for 
small sample size (only a total n=17), there was still no apparent difference (p = 0.8631).  
There was only one significant change in the data as a result of the OEV modified 
analysis; the difference between the Black and White populations was lost.  Otherwise, 
the only changes were prevalence percentages and a decrease in the significant p-values 
among groups.  Regardless, this confirms the importance of these results and this data in 
understanding the true prevalence of OPLL in Black and White populations. 
 There were a number of other features of the disease that this research was also 
able to explore.  Previously stated observations of a male bias were confirmed with 
OPLL appearing twice as often in all males in this sample than in all females.  This male 
predominance was also witnessed independently within both the Black and White 
populations, although it was more pronounced between the White males and White 
females (61% vs. 32% in the full collection, and 43% vs. 15% in the OEV-removed 
population).  In addition, research confirmed the previous reports that ossification is most 
common over 2-5 vertebrae, with an average of 3 vertebrae.  Historically, OPLL is 
thought to present most commonly on C4, C5, and C6 respectively, and was witnessed 
here mostly on C3, C4, and C5.  This data is similar enough to suggest that perhaps the 
vertebrae most involved in ossification vary by ancestral population or patient population.   
 Many more segmental cases were seen than is suggested by the literature, but this 
may be another unexpected result of looking at a skeletal collection.  It has been reported 
that up to 50% of cases may have separation between the ossified ligament and the 
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vertebral margin, which gives the typical appearance of a sharp and thin radiolucent line 
between the OPLL and the vertebra in radiographs (Enzman et al., 1994).  Therefore any 
ossification that was separated from the vertebral body by connective tissue, venous 
plexus, or crossed the intervertebral space, may have been forcibly and unintentionally 
removed during processing.  With awareness that OPLL has a significant prevalence in 
non-Asian populations, new or more careful maceration and skeletonization techniques 
can be implemented to preserve this ossification.  
 In the age group analysis, there appears to be a negative correlation between age 
and incidence in the full population and somewhat of a bell curve in the OEV-removed 
population (Figure 16).  This phenomenon will require more study in the future, but it is 
most likely a combination of a number of factors.  Such as the issue that males have twice 
the prevalence of females and are historically believed to die at a younger age, for 
example, 71% of the 80s group is comprised of females.  Thus, as the population ages, 
the individuals providing the majority of the prevalence in the population are dying 
younger and the overall prevalence can not help but decrease.  In addition, it may be that 
individuals with OPLL also have other diseases which increase mortality with age, 
however, the mortality rates of individuals with OPLL is currently unknown.  At the 
moment, this observation is more of an interesting aside until more research can be 
undertaken to better understand the underlying mechanisms influencing age group 
prevalence.   
 Lastly, these results do not seem as unexpected in comparison to previously 
reported prevalence when one considers the autopsy data coming out of Japan.  In 
looking at 350 cases, Tsuzuki (2006) reported a 20% incidence of OPLL during autopsies 
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in patients 60 and older, regardless of any clinical findings of the disease during life.  If 
more autopsy reports and skeletal collections are explored for OPLL prevalence, it is 
likely that the true prevalence of OPLL among all world populations would be better 
understood, and would be congruous with the data presented here. 
 Much of this data and analysis has provided indispensible information for the 
utility of the proposed identification technique in this research.  How these results affect 
the technique and what future analysis may be needed is discussed in the next section.  
However, it is clear that this research produced a number of highly unexpected results 
that will have profound impact far afield from the original intent, and regardless of 
OPLL’s value as an identification method.  The understanding that a disease is rare in a 
certain population may preclude a doctor from diagnosing it, but this research suggests 
that OPLL is anything but rare outside of Asian populations and should be re-evaluated in 
both the anthropological and medical communities.  
  






 The research carried out for this project has greatly contributed to the general 
understanding and presentation of AMD and OPLL.  However, the primary intent of this 
research was to consider the utility of the OPLL-BMP4-AMD relationship as a forensic 
identification method.  On any given day in the United States, there are over 100,000 active 
missing person cases and 40,000 unidentified sets of human remains.  The National Institute 
of Justice has deemed this “The Nation’s Silent Mass Disaster” based on the fact that in a 
single year there are more individuals left unidentified than there were in the aftermath of the 
9/11 attacks (Ritter, 2007).  Moreover, there is not nearly the same level of effort being put 
into the investigation of these 40,000 individuals as there was for the World Trade Center 
disaster or Hurricane Katrina.  Providing new methodologies for identification, such as the 
research presented here, can help in identifying these unknown individuals, and bring closure 
to their families.  The basic elements of a skeletal profile, DNA, and fingerprint identification 
are useful to a point.  However, when these methods are implemented and identification is 
still not possible, new analyses must be considered.   
 Anthropologists and other members of the forensic community must constantly strive 
to develop new methods and techniques that can help in the identification process.  
Biological profiles, compiled by anthropologists, are most helpful to investigators when 
there is a pool of possible candidates to compare these profiles, such as the missing 
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persons or Department of Motor Vehicles (DMV) databases.  But without outside leads, 
it is often difficult to find comprehensive and appropriate databases for comparison so 
that the resulting potential matches are strong enough, or are comprised of a reasonable 
number with which to advance the investigation.  Medical patient databases, especially 
those relating to specific diseases such as AMD, are a resource that provide considerable 
data on patients in addition to their disease state and allow for a more narrow comparison 
pool for the biological profile. 
 The operating hypothesis for this research is that given the genetic association 
between AMD and OPLL through the BMP4 SNP rs17563, the identification of OPLL on 
a set of remains would be the first step of a new method of identification through the 
genetic link of disease phenotypes in American Whites, and to a lesser degree, American 
Blacks (Figure 17).  Identification of OPLL would initiate a genetic search for the risk 
variants among all AMD subtypes to confirm the individual was at a high risk for AMD.  
With that confirmation, local AMD databases could be searched with the use of the 
biological profile to create a subset of potential matches that could aid law enforcement 
officials in there pursuit of identification. 
 This section will discuss how the results of the various research aspects of this 
project inform the utility of the proposed identification method, and the practicality of 
using genetically linked diseases as a way to increase the likelihood of identification 
through improved potential match pools.  While the exact parameters of the project 
hypothesis were not confirmed through the research, there are a number of positive 
results which will direct future OPLL-AMD research and have brought to light important 










Applicability of the Method 
 The applicability of this identification method, in terms of the research presented 
here, is defined by the parameters of the proposed hypothesis and the requirements of 
effective identification techniques.  The hypothesis stipulates that 1) the SNP rs17563 is 
the risk factor for and genetic connection between OPLL and AMD, 2) rs17563 increases 
the risk of all AMD subtypes, 3) rs17563 interacts with other risk factors for AMD, 
especially in the RORA-ROBO1-HTRA1 triumvirate, and 4) all the rs17563 associations 
are significant in at least the American White population.  Finally, for this to be a 
successful method, the skeletal disease, in this case OPLL, must have a small enough 
prevalence to be helpful in narrowing down the potential population pool.   
 Starting with the exploration of rs17563 as a risk factor for AMD, it was found 
that this SNP was in LD with another SNP, rs12898159, in the NESC cohort.  However, 
the r-value was too low to assume complete linkage between these two variants.  In 
effect, for the sake of this research, only rs17563’s influence on the pathogenesis of 
AMD is of interest.  The SNP rs17563 was found to increase the risk of all AMD 
subtypes (p = 0.0161) and dry AMD specifically (p = 0.0098), in the NESC cohort and 
the Korean cohort, respectively.  Since the NESC cohort is comprised of all White 
patients it may appear as though the results have confirmed rs17563 as an overall AMD 
risk factor in the American White population.  However, the fact that rs17563 was only 
found significant in one out of the two statistical testing methods, and that it was not 
significant in either of the other White groups suggests that the findings lack the 
repeatability and reliability necessary for an identification methodology. 
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 In regards to the cases-only interaction analysis, the results were much more 
complicated in terms of analysis.  The SNP rs17653 was associated with the four highest 
interaction analyses, two with RORA in dry patients (p = 9.78x10-9 and p = 1.51x10-5), 
and two with ROBO1 in wet patients (p = 0.0003 and p = 0.0004).  However, in order to 
get large enough n-values for the subtype analyses, the cases from all the cohorts were 
pooled together as one population.  This technique has some drawbacks, as the White 
cohorts were intermixed with the Korean cohort, the Korean cohort was the largest cohort 
in the study (almost doubling the largest White cohort), and in terms of the highest 
interaction analyses, only 25-31% of the cases in any population were dry AMD (in fact, 
the White GSSibs cohort had no dry cases).  This brings into question which groups are 
actually influencing the interaction between rs17563 and the other risk genes, as only the 
NESC and Korean cohorts showed this SNP as an independent significant risk factor for 
AMD.  On the other hand, it is a positive result that rs17563 was the only SNP to interact 
with all three risk genes tested (RORA, ROBO1, and HTRA1), and also had significant 
interactions in the wider AMD population as well as in each subtype analysis.  There is 
still the question of whether or not the interaction analyses results would remain 
significant if the Koreans were removed from the analysis. 
 Lastly, there is the consideration of the prevalence of OPLL in the White 
population.  This research has shown that the long held assumption that OPLL only 
reaches a prevalence of 1.7% among White populations is clearly flawed.  OPLL is quite 
prevalent among White skeletons analyzed, with females presenting at 32% and males at 
61%.  Unexpectedly, it was even more prevalent among the Black population, with 
results reaching 43% in females and 67% in males.  The combined prevalence in the 
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White population of 48% no longer makes OPLL an attractive target for an identification 
method for an entire ancestral population.  Even when considering the OEV-modified 
population, the prevalence among Whites was still 30%.  The presence of OPLL itself 
could discount about half to two-thirds the population, and the addition of the biological 
profile can pare down the potential matches even further, but it would not be as effective 
a tool as the project hypothesis suggested or this researcher had hoped for. 
 In taking into account the aspects of the hypothesis as it was originally presented, 
and the need for small prevalence in disease-based identification methods, this research 
was unable to support the hypothesis with the current dataset.  Thus, the proposed OPLL-
BMP4-AMD forensic identification method cannot be considered a viable technique in 
its current form.  One of the biggest concerns, which is a factor in both genetics and 
forensics, is repeatability, and unfortunately the genetic data did not have the consistency 
that would instill confidence in the current application of the method.  However, the 
results of this project do suggest that with an alteration of the hypothesis, and some 
additional research, there may be hope that in the future a version of this method will be 
helpful in solving the unidentified persons problem in the United States. 
 
Future Research 
 The main concerns of the current study are the variable results of the genetic 
analysis and lack of effectiveness of OPLL in significantly reducing the population pool.  
Both of these matters can be addressed as research into this method moves forward.  A 
reformatting of the hypothesis is imperative before any future work can be considered, 
but there are many ways in which the current hypothesis can be improved.  For instance, 
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a different population of interest can be selected besides all American Whites who suffer 
from any form of AMD.  Considering the results presented here, potentially focusing on 
only individuals who suffer from dry AMD may provide improved results, as the highest 
interaction analysis was in association with this subtype of patient.  In addition, White 
females, especially White females in the OEV-modified group (prevalence of 15%), 
could be targeted specifically as they have the lowest prevalence of OPLL in all the 
groups studied.  Perhaps this method works best on just a small subgroup of individuals 
as opposed to an entire ancestral population or sex.  Since the Koreans also showed 
significance of rs17563 as a risk factor for AMD, it may be tempting to consider an 
entirely new ancestral population for research, such as an Asian group.  However, recent 
research into the prevalence of OPLL in a Thai population suggests that not only is OPLL 
prevalence higher in Asian populations, it is more severe as well (Figure 18). 
 
 
Figure 18. OPLL in a Thai population. A C3 vertebra from a Thai male with extensive 
and severe OPLL. 
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 Besides changing the parameters of the hypothesis, additional research into the 
genetic aspect of the method would be beneficial to the project.  Taking another look at 
the interaction analysis data and removing the Korean cohort may provide a clearer 
picture as to the interaction between BMP4 and the members of the RORA-ROBO1-
HTRA1 triumvirate.  This in turn may help inform whether looking specifically at a 
subtype of the disease, such as dry AMD, would be beneficial for the method.  Also, it 
would be interesting to look at the independent risk of AMD and the interaction of the 
rs17563 SNP in a Black population.  Even though AMD is much less common among 
African Americans, a comparison of the risk factors involved may still be informative in 
a comparative capacity to see if genes are being expressed differently across populations. 
 Finally, once all the adjustments are made, the new analysis is completed, and 
hopefully an adjusted method seems viable, it would be beneficial to apply the method, 
from start to finish, on a study population.  Looking at both OPLL and AMD in an 
unknown population will help clarify the practical genetic connection between the two 
diseases, the ease of the method, and effectiveness of the resulting population pool.  Even 
though the hypothesis discussed in this research was unsuccessful, the potential for future 
research suggested by these results support the general utility of a multidisease based 
identification method, and likelihood that a form of the OPLL-BMP4-AMD identification 
method may one day be feasible.  
  
Assumptions and Issues Associated with the Method 
Although there is promise for this work, there are a number of assumptions and 
issues associated with this method of identification that must be discussed and addressed 
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before moving forward with this line of research and other similar disease association 
studies.  To begin, the method requires concurrent phenotypic expression of the diseases.  
If expression of the diseases occur at different points in the life cycle, then the method 
would be ineffective in confirming the presence of one disease with the identification of 
the other.   This fact was one of the advantages of working with OPLL and AMD as both 
diseases appear during midlife and reach their highest prevalence after the age of 50.  
Thus, for the sake of the method, identification of OPLL in a set of remains already 
suggests that the individual was older and in the right age group to present with AMD.   
It was assumed for this study that the deceased individual was aware of and had 
sought treatment for the medical disease, in this case, AMD.  While this may be a 
problem to consider in future association studies, it did not seem like a stretch in the case 
of AMD.  Since eyesight is such a vital part of one’s everyday life, it is not overly 
ambitious to assume that any significant loss or alteration in one’s central vision would 
prompt a visit to the ophthalmologist, even for the most obstinate individuals.  The one 
issue that may impede treatment is economic status.  However, this study population was 
by definition, composed of individuals who had sought treatment for the disease.  
Economic status as a hindrance to medical treatment and inclusion in the AMD databases 
is a factor which should be explored further as new research into this method is 
undertaken. 
Another issue is disease prevalence.  If a disease is very common in the local 
population, then using a disease-specific database as a comparison sample may not be 
any more informative than the local DMV records, for example, and potentially more 
troublesome.  This was the exact issue encountered as a result of the OPLL prevalence 
71 
 
study conducted on the skeletal population.  On the other hand, a very rare disease, while 
tempting to consider as a useful identification factor, can prove problematic if there is not 
enough background research to facilitate an association and only a few institutions 
throughout the country which treat the disease.   
The issue of locally available treatment centers for the disease of interest presents 
yet another potential problem.  The use of medical databases local to the recovery scene 
would be ideal, based on the assumption that the decedent was a local inhabitant and 
sought treatment for the disease at a treatment center reasonably close to his or her home.  
This is a credible assumption in the case of AMD due to its high prevalence, and it 
reduces the comparison pool to one or a few local medical institutions. 
One of the biggest concerns encountered with this method is the issue of 
confidentiality on both the part of the individual patient and the larger institution.  
Maintenance of privacy and confidentiality when it comes to patient health information is 
a must.  Fortunately, the Department of Health and Human Service’s Health Insurance 
Portability and Accountability Act (HIPAA) already stipulates regulations for the 
disclosure of personal health information to law enforcement officials (Figure 19).  It 
states that the disclosure of distinguishing physical characteristics, age, name, and contact 
information are permitted for the purpose of identifying or locating individuals such as 
missing persons.  This in itself would suggest the cooperation of medical institutions and 
the protection of patient privacy.  Moreover, informal discussions conducted with 
patients over the course of this study, suggest that they would be willing to allow 
disclosure for identification purposes, even in lieu of the HIPAA rule, as long as there is a 








Figure 19. An excerpt from the HIPAA Privacy Rule. This passage details the disclosure of personal health information (PHI) to law 




Lastly, there will be cases in which the individual does not present with the bone 
disease, and thus this technique becomes irrelevant.  However, there is no method 
employed by physical anthropologists that can be used in every case or on every set of 
remains. But, when this method is an option it has the potential of significantly cutting 
down the pool of potential matches and increasing the probability of identification.  The 
overall results on the applicability of the OPLL-BMP4-AMD manifestation of this 
method may not have been overly encouraging, but with some alterations to the research 








 Interdisciplinary research is a widely utilized form of scientific inquiry.  
Collaboration provides new perspectives on long standing hypotheses and allows for 
results which may have substantial impact on topics far beyond the researcher’s primary 
field.  Unfortunately in forensic science, interdisciplinary research is often diminished to 
interspecialty research.  While anthropologists consult with engineers and chemists, they 
usually do so under the umbrella of “forensically trained specialists.”  Moreover, the only 
medical personnel a forensic anthropologist may encounter on a regular basis is the 
medical examiner (ME), coroner, or pathologist in their jurisdiction. 
 Anthropologists bring much to the medico-legal process when dealing with 
skeletonized remains, because unlike MEs, they have the ability to procure identifying 
information from highly desiccated remains, such as age, sex, ancestry, and any unique 
bone pathologies.  The techniques employed by anthropologists to assess this information 
would benefit greatly from collaborations outside of the wider forensic community.  
Work undertaken with medical professionals, or even research informed by other 
disciplines, has the potential of providing new avenues of forensic identification and 





The work presented here is an exemplary step in the direction of forensic-medical 
collaboration for the improvement of identification methodologies.  This research was 
initiated through genetic analysis in a medical research lab and significantly informed by 
the clinical literature, with the intent of establishing an anthropological identification 
method.  The multiple perspectives helped to address the potential challenges associated 
with the method.  Moreover, due to the many disciplines involved in the undertaking of 
the project, the results provided considerable advancements in understanding the diseases 
involved in this project, far beyond the scope of the method itself. 
The discussion of this project is not complete without addressing the contributions 
of this research to each of the aspects involved, as well as the utility of the proposed 
method itself.  This research grew beyond the bounds of the original hypothesis to 
influence all the areas which informed its creation.  The OPLL-BMP4-AMD 
identification method, as it was originally proposed, may not be a currently viable 
method for identification, but the knowledge acquired in the analysis suggests that future 
research could provide a functional method, and that there is much more to the diseases 
explored than was understood at the project’s inception. 
 
BMP4 and AMD 
 BMP4 is a gene associated with many diseases in a number of diverse 
populations, and has been identified in the RORA-ROBO1-HTRA1 network as 
conferring a risk for AMD.  Interaction analysis of BMP4 and the AMD-risk triumvirate 
confirms the fact that BMP4 is being regulated in this pathway.  Moreover, its importance 
in the pathway is a factor of its functional, rather than genomic attributes.  There is much 
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more to the BMP4-AMD association than has ever been considered before.  The strong 
association between BMP4 and the dry form of AMD, as well as the differential 
interaction between BMP4 and the ROBO1 and RORA genes, suggests that BMP4 
should start to be considered on par with the RORA-ROBO1-HTRA1 triumvirate in 
future research into the pathogenesis of AMD.   
Variants in the gene can both increase risk of and protect against the development 
of AMD and its subtypes.  Differential expression of risk factors among populations 
suggests the need for a very personalized approach to the treatment of AMD and the 
development of genetic therapies.  The SNP rs17563 plays a central role in many aspects 
of BMP4’s association with AMD and may provide a novel therapeutic target for more 
than just AMD.  The association of rs17563 with both subtypes of AMD and a host of 
other diseases makes it a promising target for a multidisease treatment regime that can be 
attuned to individuals based on their particular type of AMD, other AMD risk factors 
such as ROBO1 and RORA, and any other features of their disease profile.  While BMP4 
is by no means the decisive treatment target for AMD, this work showcases its potential 
in the realm of personalized medicine, especially in an ageing population. 
 
OPLL 
 The research carried out here on the ossification of the posterior longitudinal 
ligament has challenged previous understandings of the prevalence and aspects of the 
disease in non-Asian populations.  The results presented here provide a significant 
contribution to the research of this disease and have the potential to influence future 
inquiries into OPLL.  The ability to study the disease in a large, skeletal collection has 
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allowed for new understanding that this disease is common in all populations and has a 
wide range of characteristics.  Assumptions of low prevalence in Whites and Blacks, 
along with the distribution of ossification types and location were challenged while the 
notion of a male prevalence was confirmed in all groups.  More research by both 
anthropologists and medical professionals can increase the understanding of OPLL in all 
populations, and collaboration between the two groups can define when OPLL becomes 
symptomatic and thus at what degree of ossification an informative prevalence study can 
be conducted.  There is clearly more to this disease than has ever been considered before 
in the clinical literature, and understanding that about half of the population presents with 
some degree of ossification can help clinicians understand the true potential for OPLL-
induced neurological complications as the population ages.  
 
Forensic Identification Through Disease Association 
 Regardless of the eventual success or failure of the OPLL-BMP4-AMD 
identification method, the concept of trying to associate skeletal and other medical 
diseases for forensic identification through the utilization of disease-specific databases 
should be explored further.  Medical patient databases are a valuable and underutilized 
resource in forensic identification, and anthropologists should strive to find ways to use 
them in identification, when appropriate.  Collaboration between genetic and forensic 
researchers should be the ultimate goal.  DNA and genetic research is the current gold 
standard for medico-legal cases and anthropologists should be embracing what genetics 
can add to identification instead of fearing that DNA will make anthropology obsolete.  
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The research presented here would only work with the combined support and knowledge 
of both anthropologists and medical professionals. 
In order to find the genetic connections between diseases that can foster the use of 
these databases, it is important that while creating biological profiles, anthropologists 
note features that may not be considered individuating or traditionally helpful in 
identification, and research any connections between these features and diseases of 
current medical research interest.  It is also important to consult the literature outside 
one’s primary field, as it is surprising how little communication exists across disciplines.  
OPLL is a bone disease that has been of medical and clinical interest for over 40 years, 
with entire committees dedicated to clarifying every aspect of the disease.  Yet, until this 
research it had never been looked at in a skeletal population and never considered, or in 
some cases even noticed, by anthropologists.   
Due to the constraints of the hypothesis, the composition and size of the study 
cohorts, the repeatability of the analyses, the differential genetic results between AMD 
subtypes, and the prevalence of OPLL, the identification method proposed for this 
research could not be validated.  Taking into account the issues that arose during analysis 
and the positive results of the research, there is promise that future work along with an 
alteration of the hypothesis could offer a manifestation of this project capable of being 
implemented as a recognized forensic identification technique. 
 
Final Thoughts 
 The creation of any method, whether in anthropology, genetics, or forensics is not 
an easy task.  Trying to develop an identification method drawing from all these 
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disciplines is even more complicated.  At the commencement of this research, the goal 
was only to verify the association of OPLL and AMD through the SNP rs17563 and to 
use that association as a way to utilize medical patient databases to compile a pool of 
potential matches for identification.  As this research progressed, the various aspects, 
such as BMP4 and OPLL, took on lives of their own.  The depth of research into this 
gene and disease, which was required for this project, revealed a number of unexpected 
results greatly influential beyond the identification method itself. 
 In fact, BMP4 may be a therapeutic target for AMD, and a gene almost as 
influential as the RORA-ROBO1-HTRA1 triumvirate in the risk of acquiring the disease.  
Furthermore, the results of this study would suggest that OPLL, which has been 
extensively studied for decades, is much more prevalent than ever expected, and present 
in all world populations.  This project will become the impetus for many more avenues of 
research than could have been predicted when the original research was undertaken.  The 
method may not be applicable in its current form, but the knowledge gained from the 
process, the issues identified and addressed, the exposure to research outside of 
osteology, and the opportunity for more scientific inquiry based on these results, makes 
this project a successful endeavor into the expansion of general knowledge and the 
































COMPLETE BMP4 ANALYSES 
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Table 6: Complete BMP4 SNP Analysis on All AMD Subtypes 
 
        Statistics for each study* 
Model  Study  Subgroup  Comparison  Odds  Lower  Upper   Z value  p value 
N=436  Greeks  AllAMD  rs1880add  1.048 0.618 1.776  0.174  0.8617
N=418  NESC  AllAMD (CLR)  rs1880add  0.232 0.018 2.957  ‐1.125  0.2606
Fixed           0.985 0.588 1.651  ‐0.058  0.9539
   Greeks  AllAMD  rs1880dom  1.105 0.624 1.956  0.343  0.7319
   NESC  AllAMD (CLR)  rs1880dom  0.232 0.018 2.957  ‐1.125  0.2606
Fixed           1.025 0.587 1.79  0.088  0.93
   Greeks  AllAMD  rs1880rec  0.473 0.042 5.342  ‐0.605  0.545
Fixed           0.473 0.042 5.342  ‐0.605  0.545
   Greeks  AllAMD  rs1884add  0.941 0.71 1.247  ‐0.423  0.6721
   NESC  AllAMD (CLR)  rs1884add  0.686 0.355 1.326  ‐1.12  0.2625
Fixed           0.896 0.692 1.161  ‐0.829  0.4069
   Greeks  AllAMD  rs1884dom  1.147 0.775 1.698  0.685  0.4931
   NESC  AllAMD (CLR)  rs1884dom  0.293 0.089 0.965  ‐2.018  0.0436
Fixed           1.004 0.692 1.457  0.021  0.9836
   Greeks  AllAMD  rs1884rec  0.591 0.334 1.045  ‐1.807  0.0707
   NESC  AllAMD (CLR)  rs1884rec  1.164 0.397 3.411  0.277  0.7819
Fixed           0.686 0.414 1.135  ‐1.467  0.1424
   Greeks  AllAMD  rs7563add  1.063 0.802 1.408  0.426  0.6705
N=1333   Koreans  AllAMD  rs7563add  1.098 0.909 1.326  0.971  0.3317
N=119  GSSibs  AllAMD (CLR)  rs7563add  0.644 0.192 2.161  ‐0.713  0.4761
   NESC  AllAMD (CLR)  rs7563add  1.704 1.037 2.801  2.103  0.0355
Fixed           1.123 0.968 1.302  1.528  0.1266
   Greeks  AllAMD  rs7563dom  1.209 0.761 1.921  0.803  0.4217
   Koreans  AllAMD  rs7563dom  1.159 0.725 1.853  0.616  0.5379
   GSSibs  AllAMD (CLR)  rs7563dom  0.752 0.154 3.667  ‐0.353  0.7244
   NESC  AllAMD (CLR)  rs7563dom  1.436 0.713 2.892  1.013  0.3109
Fixed           1.206 0.9 1.617  1.252  0.2105
   Greeks  AllAMD  rs7563rec  0.978 0.626 1.527  ‐0.098  0.9221
   Koreans  AllAMD  rs7563rec  1.113 0.88 1.408  0.892  0.3726
   GSSibs  AllAMD (CLR)  rs7563rec  0.438 0.05 3.82  ‐0.747  0.455
   NESC  AllAMD (CLR)  rs7563rec  2.762 1.207 6.319  2.406  0.0161
Fixed           1.135 0.928 1.387  1.232  0.2178
   Greeks  AllAMD  rs8159add  1.009 0.758 1.344  0.061  0.9512
   GSSibs  AllAMD (CLR)  rs8159add  0.432 0.113 1.647  ‐1.229  0.219
   NESC  AllAMD (CLR)  rs8159add  1.629 0.991 2.678  1.924  0.0543
Fixed           1.101 0.863 1.406  0.773  0.4395
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink.
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Table 6: Cont. 
 
        Statistics for each study* 
Model  Study  Subgroup  Comparison  Odds  Lower  Upper  Z value  p value 
   Greeks  AllAMD  rs8159dom  1.052 0.693 1.598  0.238  0.8121
   GSSibs  AllAMD (CLR)  rs8159dom  0.684 0.139 3.367  ‐0.467  0.6405
   NESC  AllAMD (CLR)  rs8159dom  1.621 0.808 3.251  1.36  0.1737
Fixed           1.149 0.81 1.63  0.78  0.4355
   Greeks  AllAMD  rs8159rec  0.952 0.569 1.593  ‐0.187  0.8514
   GSSibs  AllAMD (CLR)  rs8159rec  0.084 0.003 2.236  ‐1.479  0.1391
   NESC  AllAMD (CLR)  rs8159rec  2.25 0.925 5.472  1.788  0.0737
Fixed           1.126 0.724 1.751  0.528  0.5972
   Greeks  AllAMD  rs8820add  0.975 0.747 1.272  ‐0.186  0.8521
   Koreans  AllAMD  rs8820add  1.025 0.872 1.204  0.3  0.7642
   GSSibs  AllAMD (CLR)  rs8820add  0.604 0.185 1.97  ‐0.836  0.4032
   NESC  AllAMD (CLR)  rs8820add  0.733 0.464 1.157  ‐1.334  0.1821
Fixed           0.979 0.858 1.116  ‐0.324  0.7456
   Greeks  AllAMD  rs8820dom  1.104 0.708 1.721  0.437  0.6624
   Koreans  AllAMD  rs8820dom  1.148 0.89 1.481  1.062  0.288
   GSSibs  AllAMD (CLR)  rs8820dom  0.176 0.022 1.409  ‐1.637  0.1017
   NESC  AllAMD (CLR)  rs8820dom  0.65 0.312 1.353  ‐1.152  0.2495
Fixed           1.065 0.863 1.315  0.589  0.556
   Greeks  AllAMD  rs8820rec  0.852 0.553 1.313  ‐0.726  0.4678
   Koreans  AllAMD  rs8820rec  0.911 0.689 1.205  ‐0.653  0.514
   GSSibs  AllAMD (CLR)  rs8820rec  2.329 0.275 19.741  0.775  0.4382
   NESC  AllAMD (CLR)  rs8820rec  0.715 0.357 1.431  ‐0.948  0.3433
Fixed           0.882 0.707 1.101  ‐1.11  0.267
   Greeks  AllAMD  rs1880add  1.048 0.618 1.776  0.174  0.8617
   NESC  AllAMD (GEE)  rs1880add  1.241 0.484 3.184  0.449  0.6537
Fixed           1.091 0.689 1.729  0.371  0.7105
   Greeks  AllAMD  rs1880dom  1.105 0.624 1.956  0.343  0.7319
   NESC  AllAMD (GEE)  rs1880dom  1.184 0.432 3.244  0.329  0.7422
Fixed           1.124 0.684 1.847  0.46  0.6454
   Greeks  AllAMD  rs1880rec  0.473 0.042 5.342  ‐0.605  0.545
Fixed           0.473 0.042 5.342  ‐0.605  0.545
   Greeks  AllAMD  rs1884add  0.941 0.71 1.247  ‐0.423  0.6721
   NESC  AllAMD (GEE)  rs1884add  1.019 0.756 1.375  0.126  0.8994
Fixed           0.977 0.796 1.199  ‐0.221  0.8247
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink.
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Table 6: Cont. 
 
        Statistics for each study* 
Model  Study  Subgroup  Comparison Odds  Lower  Upper  Z value  p value 
   Greeks  AllAMD  rs1884dom  1.147 0.775 1.698  0.685  0.4931
   NESC  AllAMD (GEE)  rs1884dom  1.013 0.662 1.55  0.061  0.9515
Fixed           1.083 0.812 1.445  0.545  0.5857
   Greeks  AllAMD  rs1884rec  0.591 0.334 1.045  ‐1.807  0.0707
   NESC  AllAMD (GEE)  rs1884rec  1.053 0.591 1.877  0.176  0.8606
Fixed           0.786 0.524 1.179  ‐1.163  0.2447
   Greeks  AllAMD  rs7563add  1.063 0.802 1.408  0.426  0.6705
   Koreans  AllAMD  rs7563add  1.098 0.909 1.326  0.971  0.3317
   GSSibs  AllAMD (GEE)  rs7563add  0.896 0.502 1.597  ‐0.373  0.7093
   NESC  AllAMD (GEE)  rs7563add  1.166 0.927 1.468  1.312  0.1894
Fixed           1.1 0.97 1.248  1.481  0.1386
   Greeks  AllAMD  rs7563dom  1.209 0.761 1.921  0.803  0.4217
   Koreans  AllAMD  rs7563dom  1.159 0.725 1.853  0.616  0.5379
   GSSibs  AllAMD (GEE)  rs7563dom  0.785 0.356 1.731  ‐0.599  0.549
   NESC  AllAMD (GEE)  rs7563dom  1.385 0.932 2.059  1.611  0.1071
Fixed           1.208 0.949 1.538  1.534  0.125
   Greeks  AllAMD  rs7563rec  0.978 0.626 1.527  ‐0.098  0.9221
   Koreans  AllAMD  rs7563rec  1.113 0.88 1.408  0.892  0.3726
   GSSibs  AllAMD (GEE)  rs7563rec  1.111 0.287 4.298  0.153  0.8784
   NESC  AllAMD (GEE)  rs7563rec  1.09 0.771 1.54  0.488  0.6257
Fixed           1.085 0.909 1.294  0.9  0.3679
   Greeks  AllAMD  rs8159add  1.009 0.758 1.344  0.061  0.9512
   GSSibs  AllAMD (GEE)  rs8159add  0.996 0.532 1.866  ‐0.011  0.991
   NESC  AllAMD (GEE)  rs8159add  1.175 0.92 1.502  1.291  0.1968
Fixed           1.093 0.914 1.307  0.975  0.3295
   Greeks  AllAMD  rs8159dom  1.052 0.693 1.598  0.238  0.8121
   GSSibs  AllAMD (GEE)  rs8159dom  0.963 0.432 2.151  ‐0.091  0.9277
   NESC  AllAMD (GEE)  rs8159dom  1.369 0.929 2.017  1.586  0.1127
Fixed           1.181 0.904 1.544  1.219  0.223
 
* Results of meta-analysis under three different genetic models (additive, dominant, and 








Table 6: Cont. 
 
        Statistics for each study* 
Model  Study  Subgroup  Comparison  Odds  Lower  Upper  Z value  p value 
   Greeks  AllAMD  rs8159rec  0.952 0.569 1.593  ‐0.187  0.8514
   GSSibs  AllAMD (GEE)  rs8159rec  1.069 0.26 4.4  0.093  0.9259
   NESC  AllAMD (GEE)  rs8159rec  1.088 0.748 1.584  0.442  0.6582
Fixed           1.04 0.773 1.399  0.261  0.794
   Greeks  AllAMD  rs8820add  0.975 0.747 1.272  ‐0.186  0.8521
   Koreans  AllAMD  rs8820add  1.025 0.872 1.204  0.3  0.7642
   GSSibs  AllAMD (GEE)  rs8820add  0.654 0.347 1.232  ‐1.315  0.1886
   NESC  AllAMD (GEE)  rs8820add  0.962 0.768 1.206  ‐0.333  0.7392
Fixed           0.984 0.876 1.104  ‐0.277  0.7819
   Greeks  AllAMD  rs8820dom  1.104 0.708 1.721  0.437  0.6624
   Koreans  AllAMD  rs8820dom  1.148 0.89 1.481  1.062  0.288
   GSSibs  AllAMD (GEE)  rs8820dom  0.335 0.118 0.947  ‐2.063  0.0391
   NESC  AllAMD (GEE)  rs8820dom  0.929 0.643 1.341  ‐0.394  0.6936
Fixed           1.038 0.862 1.25  0.391  0.6958
   Greeks  AllAMD  rs8820rec  0.852 0.553 1.313  ‐0.726  0.4678
   Koreans  AllAMD  rs8820rec  0.911 0.689 1.205  ‐0.653  0.514
   GSSibs  AllAMD (GEE)  rs8820rec  0.95 0.34 2.652  ‐0.098  0.9218
   NESC  AllAMD (GEE)  rs8820rec  0.973 0.657 1.442  ‐0.136  0.8921
Fixed           0.915 0.751 1.115  ‐0.881  0.3783
 
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink.
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Table 7: Complete BMP4 SNP Analysis on Neovascular AMD 
 
        Statistics for each study 
Model  Study  Subgroup  Comparison Odds  Lower  Upper  Z value 
p 
value 
N=436   Greeks  NeoNorm  rs1880add  0.844 0.45 1.583  ‐0.528  0.5973
N=418   NESC  NeoNorm (CLR) rs1880add  0.222 0.017 2.904  ‐1.147  0.2512
Fixed           0.783 0.425 1.442  ‐0.786  0.4319
   Greeks  NeoNorm  rs1880dom  0.828 0.413 1.661  ‐0.531  0.5952
   NESC  NeoNorm (CLR) rs1880dom  0.222 0.017 2.904  ‐1.147  0.2512
Fixed           0.757 0.386 1.482  ‐0.813  0.4163
   Greeks  NeoNorm  rs1880rec  0.788 0.068 9.102  ‐0.191  0.8486
Fixed           0.788 0.068 9.102  ‐0.191  0.8486
   Greeks  NeoNorm  rs1884add  0.859 0.623 1.184  ‐0.928  0.3535
   NESC  NeoNorm (CLR) rs1884add  0.634 0.307 1.309  ‐1.232  0.218
Fixed           0.817 0.609 1.096  ‐1.347  0.1779
   Greeks  NeoNorm  rs1884dom  1.05 0.672 1.64  0.214  0.8303
   NESC  NeoNorm (CLR) rs1884dom  0.195 0.046 0.822  ‐2.227  0.0259
Fixed           0.906 0.592 1.387  ‐0.455  0.6491
   Greeks  NeoNorm  rs1884rec  0.465 0.23 0.94  ‐2.132  0.033
   NESC  NeoNorm (CLR) rs1884rec  1.199 0.379 3.794  0.309  0.7575
Fixed           0.602 0.33 1.097  ‐1.658  0.0973
   Greeks  NeoNorm  rs7563add  1.167 0.848 1.607  0.947  0.3436
N=1333   Koreans  NeoNorm  rs7563add  1.005 0.807 1.252  0.045  0.9645
N=119   GSSibs  NeoNorm (CLR) rs7563add  0.644 0.192 2.161  ‐0.713  0.4761
   NESC  NeoNorm (CLR) rs7563add  1.447 0.828 2.53  1.296  0.1949
Fixed           1.075 0.907 1.275  0.835  0.4038
   Greeks  NeoNorm  rs7563dom  1.291 0.751 2.219  0.925  0.3552
   Koreans  NeoNorm  rs7563dom  1.112 0.645 1.917  0.382  0.7024
   GSSibs  NeoNorm (CLR) rs7563dom  0.752 0.154 3.667  ‐0.353  0.7244
   NESC  NeoNorm (CLR) rs7563dom  1.488 0.658 3.365  0.955  0.3398
Fixed           1.218 0.867 1.71  1.139  0.2547
   Greeks  NeoNorm  rs7563rec  1.172 0.712 1.93  0.624  0.5329
   Koreans  NeoNorm  rs7563rec  0.98 0.744 1.291  ‐0.144  0.8857
   GSSibs  NeoNorm (CLR) rs7563rec  0.438 0.05 3.82  ‐0.747  0.455
   NESC  NeoNorm (CLR) rs7563rec  1.786 0.677 4.709  1.172  0.241
Fixed           1.045 0.828 1.319  0.371  0.7109
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink.
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Table 7: Cont. 
 
        Statistics for each study 
Model  Study  Subgroup  Comparison  Odds  Lower  Upper  Z value  p value
   Greeks  NeoNorm  rs8159add  1.171 0.848 1.618  0.958  0.3382
   GSSibs  NeoNorm (CLR)  rs8159add  0.432 0.113 1.647  ‐1.229  0.219
   NESC  NeoNorm (CLR)  rs8159add  1.523 0.871 2.663  1.476  0.1401
Fixed           1.196 0.91 1.573  1.283  0.1994
   Greeks  NeoNorm  rs8159dom  1.219 0.748 1.987  0.795  0.4269
   GSSibs  NeoNorm (CLR)  rs8159dom  0.684 0.139 3.367  ‐0.467  0.6405
   NESC  NeoNorm (CLR)  rs8159dom  1.843 0.819 4.148  1.477  0.1397
Fixed           1.302 0.868 1.951  1.277  0.2017
   Greeks  NeoNorm  rs8159rec  1.241 0.708 2.175  0.754  0.4506
   GSSibs  NeoNorm (CLR)  rs8159rec  0.084 0.003 2.236  ‐1.479  0.1391
   NESC  NeoNorm (CLR)  rs8159rec  1.553 0.575 4.197  0.868  0.3855
Fixed           1.234 0.761 2.001  0.854  0.3932
   Greeks  NeoNorm  rs8820add  0.903 0.667 1.223  ‐0.659  0.51
   Koreans  NeoNorm  rs8820add  0.922 0.761 1.117  ‐0.831  0.4057
   GSSibs  NeoNorm (CLR)  rs8820add  0.604 0.185 1.97  ‐0.836  0.4032
   NESC  NeoNorm (CLR)  rs8820add  0.784 0.464 1.325  ‐0.908  0.3636
Fixed           0.898 0.77 1.047  ‐1.373  0.1697
   Greeks  NeoNorm  rs8820dom  1.012 0.612 1.673  0.046  0.9629
   Koreans  NeoNorm  rs8820dom  1.14 0.845 1.537  0.859  0.3906
   GSSibs  NeoNorm (CLR)  rs8820dom  0.176 0.022 1.409  ‐1.637  0.1017
   NESC  NeoNorm (CLR)  rs8820dom  0.643 0.265 1.561  ‐0.976  0.329
Fixed           1.034 0.809 1.321  0.264  0.7921
   Greeks  NeoNorm  rs8820rec  0.748 0.45 1.243  ‐1.121  0.2623
   Koreans  NeoNorm  rs8820rec  0.645 0.452 0.92  ‐2.419  0.0156
   GSSibs  NeoNorm (CLR)  rs8820rec  2.329 0.275 19.74  0.775  0.4382
   NESC  NeoNorm (CLR)  rs8820rec  0.824 0.378 1.795  ‐0.487  0.6261
Fixed           0.707 0.54 0.927  ‐2.51  0.0121
   Greeks  NeoNorm  rs1880add  0.844 0.45 1.583  ‐0.528  0.5973
   NESC  NeoNorm(GEE)  rs1880add  1.33 0.476 3.718  0.544  0.5866
Fixed           0.955 0.559 1.634  ‐0.167  0.8676
 
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink.
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Table 7: Cont. 
 
        Statistics for each study 
Model  Study  Subgroup  Comparison Odds  Lower  Upper 
Z 
value  p value 
   Greeks  NeoNorm  rs1880dom  0.828 0.413 1.661  ‐0.531  0.5952
   NESC  NeoNorm (GEE) rs1880dom  1.33 0.476 3.718  0.544  0.5866
Fixed           0.961 0.54 1.71  ‐0.135  0.8925
   Greeks  NeoNorm  rs1880rec  0.788 0.068 9.102  ‐0.191  0.8486
Fixed           0.788 0.068 9.102  ‐0.191  0.8486
   Greeks  NeoNorm  rs1884add  0.859 0.623 1.184  ‐0.928  0.3535
   NESC  NeoNorm (GEE) rs1884add  1.042 0.781 1.392  0.282  0.7779
Fixed           0.956 0.771 1.185  ‐0.411  0.6809
   Greeks  NeoNorm  rs1884dom  1.05 0.672 1.64  0.214  0.8303
   NESC  NeoNorm (GEE) rs1884dom  0.995 0.665 1.487  ‐0.026  0.9794
Fixed           1.019 0.756 1.374  0.124  0.9011
   Greeks  NeoNorm  rs1884rec  0.465 0.23 0.94  ‐2.132  0.033
   NESC  NeoNorm (GEE) rs1884rec  1.195 0.667 2.14  0.599  0.5493
Fixed           0.814 0.52 1.275  ‐0.898  0.3691
   Greeks  NeoNorm  rs7563add  1.167 0.848 1.607  0.947  0.3436
   Koreans  NeoNorm  rs7563add  1.005 0.807 1.252  0.045  0.9645
   GSSibs  NeoNorm (GEE) rs7563add  0.896 0.502 1.597  ‐0.373  0.7093
   NESC  NeoNorm (GEE) rs7563add  2.114 1.702 2.627  6.762  0~
Fixed           1.369 1.196 1.567  4.552  0~
   Greeks  NeoNorm  rs7563dom  1.291 0.751 2.219  0.925  0.3552
   Koreans  NeoNorm  rs7563dom  1.112 0.645 1.917  0.382  0.7024
   GSSibs  NeoNorm (GEE) rs7563dom  0.785 0.356 1.731  ‐0.599  0.549
   NESC  NeoNorm (GEE) rs7563dom  1.392 0.921 2.103  1.571  0.1162
Fixed           1.216 0.933 1.584  1.446  0.1482
   Greeks  NeoNorm  rs7563rec  1.172 0.712 1.93  0.624  0.5329
   Koreans  NeoNorm  rs7563rec  0.98 0.744 1.291  ‐0.144  0.8857
   GSSibs  NeoNorm (GEE) rs7563rec  1.111 0.287 4.298  0.153  0.8784
   NESC  NeoNorm (GEE) rs7563rec  3.261 2.265 4.695  6.357  0~
Fixed           1.447 1.186 1.765  3.638  0.0003
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink. 
~P-value is not actually significant; it is an error of convergence in SAS.
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Table 7: Cont. 
 
        Statistics for each study 
Model  Study  Subgroup  Comparison Odds  Lower  Upper  Z value 
p 
value 
   Greeks  NeoNorm  rs8159add  1.171 0.848 1.618  0.958  0.3382
   GSSibs  NeoNorm (GEE)  rs8159add  0.996 0.532 1.866  ‐0.011  0.991
   NESC  NeoNorm (GEE)  rs8159add  2.488 2.144 2.886  12.036  0
Fixed           2.107 1.847 2.404  11.081  0
   Greeks  NeoNorm  rs8159dom  1.219 0.748 1.987  0.795  0.4269
   GSSibs  NeoNorm (GEE)  rs8159dom  0.963 0.432 2.151  ‐0.091  0.9277
   NESC  NeoNorm (GEE)  rs8159dom  1.686 1.036 2.744  2.102  0.0355
Fixed           1.348 0.982 1.851  1.848  0.0646
   Greeks  NeoNorm  rs8159rec  1.241 0.708 2.175  0.754  0.4506
   GSSibs  NeoNorm (GEE)  rs8159rec  1.069 0.26 4.4  0.093  0.9259
   NESC  NeoNorm (GEE)  rs8159rec  2.053 1.035 4.071  2.059  0.0395
Fixed           1.474 0.973 2.232  1.833  0.0669
   Greeks  NeoNorm  rs8820add  0.903 0.667 1.223  ‐0.659  0.51
   Koreans  NeoNorm  rs8820add  0.922 0.761 1.117  ‐0.831  0.4057
   GSSibs  NeoNorm (GEE)  rs8820add  0.654 0.347 1.232  ‐1.315  0.1886
   NESC  NeoNorm (GEE)  rs8820add  1.623 1.127 2.337  2.605  0.0092
Fixed           0.985 0.853 1.137  ‐0.208  0.8351
   Greeks  NeoNorm  rs8820dom  1.012 0.612 1.673  0.046  0.9629
   Koreans  NeoNorm  rs8820dom  1.14 0.845 1.537  0.859  0.3906
   GSSibs  NeoNorm (GEE)  rs8820dom  0.335 0.118 0.947  ‐2.063  0.0391
   NESC  NeoNorm (GEE)  rs8820dom  1.944 1.042 3.625  2.091  0.0366
Fixed           1.126 0.893 1.42  1.004  0.3153
   Greeks  NeoNorm  rs8820rec  0.748 0.45 1.243  ‐1.121  0.2623
   Koreans  NeoNorm  rs8820rec  0.645 0.452 0.92  ‐2.419  0.0156
   GSSibs  NeoNorm (GEE)  rs8820rec  0.95 0.34 2.652  ‐0.098  0.9218
   NESC  NeoNorm (GEE)  rs8820rec  2.308 1.16 4.592  2.383  0.0172
Fixed           0.824 0.636 1.068  ‐1.465  0.143
 
* Results of meta-analysis under three different genetic models (additive, dominant, and 








Table 8: Complete BMP4 SNP Analysis on Dry AMD 
        Statistics for each study 





N=436   Greeks  DryNorm  rs1880add  1.594 0.815 3.118  1.362  0.1732
Fixed           1.594 0.815 3.118  1.362  0.1732
   Greeks  DryNorm  rs1880dom  1.845 0.898 3.791  1.667  0.0955
Fixed           1.845 0.898 3.791  1.667  0.0955
   Greeks  DryNorm  rs1884add  1.024 0.689 1.521  0.117  0.9065
Fixed           1.024 0.689 1.521  0.117  0.9065
   Greeks  DryNorm  rs1884dom  1.254 0.701 2.243  0.763  0.4454
Fixed           1.254 0.701 2.243  0.763  0.4454
   Greeks  DryNorm  rs1884rec  0.712 0.311 1.63  ‐0.804  0.4213
Fixed           0.712 0.311 1.63  ‐0.804  0.4213
   Greeks  DryNorm  rs7563add  0.959 0.637 1.445  ‐0.2  0.8413
N=1333  Koreans  DryNorm  rs7563add  1.46 1.073 1.987  2.408  0.0161
N=418   NESC  DryNorm (CLR) rs7563add  4.204 0.668 26.45  1.53  0.126
Fixed           1.281 1.004 1.636  1.991  0.0464
   Greeks  DryNorm  rs7563dom  1.286 0.648 2.553  0.719  0.4721
   Koreans  DryNorm  rs7563dom  1.394 0.64 3.037  0.836  0.403
   NESC  DryNorm (CLR) rs7563dom  0.956 0.134 6.827  ‐0.045  0.9642
Fixed           1.304 0.793 2.145  1.045  0.2959
   Greeks  DryNorm  rs7563rec  0.688 0.34 1.392  ‐1.04  0.2983
   Koreans  DryNorm  rs7563rec  1.631 1.126 2.363  2.585  0.0097
Fixed           1.353 0.974 1.878  1.804  0.0713
   Greeks  DryNorm  rs8159add  0.773 0.505 1.184  ‐1.184  0.2362
   NESC  DryNorm (CLR) rs8159add  2 0.341 11.73  0.768  0.4426
Fixed           0.814 0.538 1.232  ‐0.972  0.3311
   Greeks  DryNorm  rs8159dom  0.846 0.471 1.521  ‐0.559  0.5762
   NESC  DryNorm (CLR) rs8159dom  0.66 0.084 5.194  ‐0.395  0.693
Fixed           0.83 0.472 1.46  ‐0.646  0.5186
   Greeks  DryNorm  rs8159rec  0.506 0.202 1.266  ‐1.456  0.1455
Fixed           0.506 0.202 1.266  ‐1.456  0.1455
   Greeks  DryNorm  rs8820add  1.082 0.739 1.584  0.405  0.6853
   Koreans  DryNorm  rs8820add  1.184 0.928 1.511  1.358  0.1744
   NESC  DryNorm (CLR) rs8820add  0.632 0.15 2.665  ‐0.625  0.532
Fixed           1.14 0.93 1.397  1.261  0.2075
* Results of meta-analysis under three different genetic models (additive, dominant, and 
recessive) for all AMD subtypes, after adjustment for age and sex.  Significance in pink. 
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Table 8: Cont. 
 
        Statistics for each study 





   Greeks  DryNorm  rs8820dom  1.282 0.654 2.514  0.723  0.4696
   Koreans  DryNorm  rs8820dom  1.171 0.788 1.741  0.78  0.4354
   NESC  DryNorm (CLR)  rs8820dom  0.537 0.075 3.853  ‐0.618  0.5363
Fixed           1.171 0.836 1.64  0.918  0.3585
   Greeks  DryNorm  rs8820rec  0.989 0.536 1.825  ‐0.035  0.9718
   Koreans  DryNorm  rs8820rec  1.363 0.911 2.04  1.505  0.1323
   NESC  DryNorm (CLR)  rs8820rec  0.774 0.09 6.646  ‐0.234  0.8154
Fixed           1.223 0.877 1.706  1.187  0.2354
   Greeks  DryNorm  rs1880add  1.594 0.815 3.118  1.362  0.1732
   NESC  DryNorm (GEE)  rs1880add  0.945 0.244 3.654  ‐0.082  0.9349
Fixed           1.438 0.788 2.622  1.184  0.2364
   Greeks  DryNorm  rs1880dom  1.845 0.898 3.791  1.667  0.0955
   NESC  DryNorm (GEE)  rs1880dom  0.615 0.13 2.902  ‐0.614  0.5394
Fixed           1.519 0.79 2.918  1.254  0.21
   Greeks  DryNorm  rs1884add  1.024 0.689 1.521  0.117  0.9065
   NESC  DryNorm (GEE)  rs1884add  1.14 0.662 1.962  0.473  0.6362
Fixed           1.063 0.772 1.464  0.374  0.7087
   Greeks  DryNorm  rs1884dom  1.254 0.701 2.243  0.763  0.4454
   NESC  DryNorm (GEE)  rs1884dom  1.326 0.601 2.925  0.698  0.4853
Fixed           1.279 0.8 2.043  1.028  0.3039
   Greeks  DryNorm  rs1884rec  0.712 0.311 1.63  ‐0.804  0.4213
   NESC  DryNorm (GEE)  rs1884rec  0.84 0.342 2.06  ‐0.381  0.7029
Fixed           0.768 0.418 1.412  ‐0.85  0.3956
   Greeks  DryNorm  rs7563add  0.959 0.637 1.445  ‐0.2  0.8413
   Koreans  DryNorm  rs7563add  1.46 1.073 1.987  2.408  0.0161
   NESC  DryNorm (GEE)  rs7563add  1.082 0.779 1.503  0.47  0.6385
Fixed           1.189 0.977 1.449  1.726  0.0844
   Greeks  DryNorm  rs7563dom  1.286 0.648 2.553  0.719  0.4721
   Koreans  DryNorm  rs7563dom  1.394 0.64 3.037  0.836  0.403
   NESC  DryNorm (GEE)  rs7563dom  1.225 0.715 2.098  0.738  0.4606
Fixed           1.28 0.882 1.856  1.299  0.1938
 
* Results of meta-analysis under three different genetic models (additive, dominant, and 







Table 8: Cont. 
 
        Statistics for each study 





   Greeks  DryNorm  rs7563rec  0.688 0.34 1.392  ‐1.04  0.2983
   Koreans  DryNorm  rs7563rec  1.631 1.126 2.363  2.585  0.0097
   NESC  DryNorm (GEE)  rs7563rec  0.989 0.549 1.781  ‐0.037  0.9705
Fixed           1.256 0.943 1.672  1.557  0.1194
   Greeks  DryNorm  rs8159add  0.773 0.505 1.184  ‐1.184  0.2362
   NESC  DryNorm (GEE)  rs8159add  0.961 0.69 1.338  ‐0.235  0.8141
Fixed           0.885 0.682 1.15  ‐0.912  0.3616
   Greeks  DryNorm  rs8159dom  0.846 0.471 1.521  ‐0.559  0.5762
   NESC  DryNorm (GEE)  rs8159dom  1.047 0.632 1.736  0.178  0.8587
Fixed           0.956 0.652 1.402  ‐0.23  0.818
   Greeks  DryNorm  rs8159rec  0.506 0.202 1.266  ‐1.456  0.1455
   NESC  DryNorm (GEE)  rs8159rec  0.808 0.425 1.537  ‐0.65  0.5156
Fixed           0.692 0.409 1.172  ‐1.368  0.1713
   Greeks  DryNorm  rs8820add  1.082 0.739 1.584  0.405  0.6853
   Koreans  DryNorm  rs8820add  1.184 0.928 1.511  1.358  0.1744
   NESC  DryNorm (GEE)  rs8820add  0.979 0.698 1.374  ‐0.121  0.9038
Fixed           1.104 0.926 1.316  1.103  0.2702
   Greeks  DryNorm  rs8820dom  1.282 0.654 2.514  0.723  0.4696
   Koreans  DryNorm  rs8820dom  1.171 0.788 1.741  0.78  0.4354
   NESC  DryNorm (GEE)  rs8820dom  1.003 0.58 1.734  0.011  0.9911
Fixed           1.14 0.853 1.524  0.887  0.375
   Greeks  DryNorm  rs8820rec  0.989 0.536 1.825  ‐0.035  0.9718
   Koreans  DryNorm  rs8820rec  1.363 0.911 2.04  1.505  0.1323
   NESC  DryNorm (GEE)  rs8820rec  0.943 0.527 1.685  ‐0.2  0.8416
Fixed           1.155 0.863 1.546  0.97  0.3319
 
* Results of meta-analysis under three different genetic models (additive, dominant, and 







Table 9: Complete Cases-only Interaction Analysis 
 
Cases Only ‐ All 


















BMP4 rs12898159  1.011  0.837  1.222  0.9065  1.035  0.828  1.292  0.7637  0.86  0.579  1.277  0.4544 
HTRA1 rs11200638*     
BMP4 rs12898159  1.023  0.849  1.233  0.8124  1.074  0.864  1.336  0.5186  0.828  0.556  1.234  0.3542 
HTRA1 rs1049331*       
BMP4 rs12898159  1.02  0.851  1.222  0.8296  1.053  0.85  1.306  0.6357  0.857  0.59  1.244  0.4155 
RORA rs730754*           
BMP4 rs12898159  0.89  0.725  1.091  0.2617  0.84  0.656  1.077  0.1687  1.181  0.796  1.753  0.4089 
RORA rs12900948*       
BMP4 rs12898159  0.911  0.743  1.117  0.3711  0.866  0.674  1.112  0.2585  1.111  0.751  1.645  0.5974 
RORA rs8034864*         
BMP4 rs12898159  0.832  0.658  1.052  0.124  0.714  0.538  0.948  0.0197  1.43  0.892  2.292  0.1372 
RORA rs4335725*         
BMP4 rs12898159  1.024  0.809  1.296  0.8452  1.084  0.822  1.428  0.5675  0.864  0.525  1.422  0.5657 
ROBO1 rs1387665*      
BMP4 rs12898159  0.811  0.664  0.99  0.0395  0.741  0.585  0.939  0.0133  0.964  0.636  1.459  0.8614 
ROBO1 rs4513416*      
BMP4 rs12898159  1.242  1.017  1.518  0.034  1.409  1.11  1.789  0.0048  1.01  0.665  1.533  0.9634 
ROBO1 rs9309833*      
BMP4 rs12898159  0.872  0.677  1.125  0.2919  0.856  0.623  1.175  0.3355  0.819  0.512  1.311  0.4058 
ARMS2 rs10490924*    
BMP4 rs17563  1.197  1.028  1.393  0.0206  1.18  0.978  1.424  0.0838  1.252  0.938  1.67  0.1268 
HTRA1 rs11200638*     
BMP4 rs17563  1.275  1.097  1.483  0.0016  1.211  1.007  1.456  0.0422  1.417  1.06  1.894  0.0186 
HTRA1 rs1049331*       
BMP4 rs17563  1.246  1.073  1.446  0.004  1.183  0.984  1.422  0.0734  1.37  1.028  1.824  0.0314 
* Summary of significant cases-only interaction analysis between the BMP4 SNPs and SNPs from the RORA-ROBO1-HTRA1 
triumvirate among all cases and wet (Neo) and dry cases specifically (significant interactions are in pink). 
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BMP4 rs17563  1.32  1.136  1.533  0.0003  1.163  0.967  1.398  0.1086  1.928  1.432  2.596  1.51E‐05 
RORA rs12900948*      
BMP4 rs17563  1.156  0.995  1.344  0.0582  1.095  0.909  1.32  0.3389  1.343  1.004  1.797  0.0467 
RORA rs8034864*         
BMP4 rs17563  1.474  1.27  1.711  3.47E‐07  1.267  1.055  1.522  0.0114  2.438  1.798  3.307  9.78E‐09 
RORA rs4335725*         
BMP4 rs17563  0.982  0.775  1.244  0.8802  1.038  0.788  1.367  0.7928  0.884  0.532  1.468  0.6328 
ROBO1 rs1387665*      
BMP4 rs17563  0.76  0.653  0.885  0.0004  0.71  0.591  0.853  0.0003  0.853  0.627  1.16  0.3098 
ROBO1 rs4513416*      
BMP4 rs17563  1.268  1.089  1.477  0.0023  1.399  1.161  1.687  0.0004  1.096  0.813  1.478  0.5455 
ROBO1 rs9309833*      
BMP4 rs17563  1.13  0.953  1.339  0.1595  1.121  0.902  1.394  0.3037  0.973  0.715  1.323  0.8609 
ARMS2 rs10490924*    
BMP4 rs2761880  1.04  0.693  1.562  0.8497  1.229  0.733  2.063  0.434  0.943  0.454  1.96  0.8751 
HTRA1 rs11200638*     
BMP4 rs2761880  1.043  0.7  1.555  0.8363  1.192  0.721  1.97  0.4928  0.959  0.458  2.007  0.9113 
HTRA1 rs1049331*       
BMP4 rs2761880  0.979  0.667  1.436  0.9131  1.122  0.686  1.835  0.6466  0.83  0.414  1.662  0.5981 
RORA rs730754*           
BMP4 rs2761880  1.146  0.72  1.825  0.5652  1.194  0.634  2.25  0.5823  0.933  0.455  1.914  0.8499 
RORA rs12900948*      
BMP4 rs2761880  1.015  0.635  1.62  0.9515  1.033  0.549  1.945  0.9196  0.765  0.367  1.595  0.4755 
RORA rs8034864*         
BMP4 rs2761880  1.099  0.671  1.801  0.7079  1.591  0.856  2.958  0.1422  0.434  0.136  1.391  0.1602 
* Summary of significant cases-only interaction analysis between the BMP4 SNPs and SNPs from the RORA-ROBO1-HTRA1 
triumvirate among all cases and wet (Neo) and dry cases specifically (significant interactions are in pink). 93 
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BMP4 rs2761880  0.841  0.504  1.403  0.5073  0.722  0.367  1.423  0.3469  1.372  0.592  3.178  0.4611 
ROBO1 rs1387665*      
BMP4 rs2761880  1.051  0.673  1.641  0.8282  1.014  0.578  1.781  0.9609  1.193  0.542  2.629  0.6607 
ROBO1 rs4513416*      
BMP4 rs2761880  1.068  0.685  1.667  0.7714  0.977  0.549  1.736  0.9362  1.284  0.605  2.726  0.515 
ROBO1 rs9309833*      
BMP4 rs2761880  1.128  0.647  1.968  0.6709  1.513  0.742  3.086  0.2545  0.821  0.313  2.156  0.6892 
ARMS2 rs10490924*    
BMP4 rs2761884  1.068  0.858  1.329  0.5581  1.061  0.821  1.371  0.6509  1.148  0.712  1.85  0.5715 
HTRA1 rs11200638*     
BMP4 rs2761884  1.022  0.824  1.268  0.8417  1.008  0.785  1.295  0.9477  1.148  0.708  1.862  0.576 
HTRA1 rs1049331*       
BMP4 rs2761884  0.99  0.805  1.216  0.9211  0.996  0.78  1.272  0.9724  1.015  0.652  1.58  0.9477 
RORA rs730754*           
BMP4 rs2761884  1.058  0.826  1.356  0.6548  1.102  0.811  1.498  0.5328  0.933  0.583  1.494  0.7735 
RORA rs12900948*       
BMP4 rs2761884  1.032  0.806  1.322  0.8029  1.086  0.801  1.474  0.5953  0.994  0.619  1.597  0.9805 
RORA rs8034864*         
BMP4 rs2761884  1.154  0.878  1.518  0.3052  1.182  0.844  1.656  0.3305  1.087  0.642  1.84  0.7556 
RORA rs4335725*         
BMP4 rs2761884  1.207  0.927  1.573  0.1623  1.251  0.917  1.707  0.1575  1.051  0.596  1.851  0.8641 
ROBO1 rs1387665*      
BMP4 rs2761884  1.424  1.115  1.817  0.0046  1.303  0.975  1.742  0.0735  1.685  1.018  2.79  0.0426 
ROBO1 rs4513416*      
BMP4 rs2761884  0.753  0.592  0.959  0.0213  0.683  0.512  0.912  0.0098  0.976  0.601  1.586  0.9232 
* Summary of significant cases-only interaction analysis between the BMP4 SNPs and SNPs from the RORA-ROBO1-HTRA1 
triumvirate among all cases and wet (Neo) and dry cases specifically (significant interactions are in pink). 94 
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BMP4 rs2761884  0.91  0.667  1.241  0.5509  1.025  0.689  1.525  0.9035  0.905  0.516  1.588  0.7277 
ARMS2 rs10490924*    
BMP4 rs4898820  0.94  0.806  1.096  0.4287  0.984  0.812  1.192  0.8669  0.855  0.641  1.141  0.2868 
HTRA1 rs11200638*     
BMP4 rs4898820  0.933  0.801  1.087  0.3742  0.982  0.812  1.186  0.8471  0.805  0.603  1.075  0.1419 
HTRA1 rs1049331*       
BMP4 rs4898820  0.942  0.81  1.095  0.4331  1.001  0.829  1.208  0.992  0.78  0.588  1.035  0.0847 
RORA rs730754*           
BMP4 rs4898820  1.022  0.88  1.187  0.778  1.107  0.918  1.334  0.2868  0.731  0.549  0.973  0.0318 
RORA rs12900948*       
BMP4 rs4898820  0.98  0.843  1.14  0.7968  1.075  0.89  1.298  0.4547  0.745  0.559  0.992  0.0436 
RORA rs8034864*         
BMP4 rs4898820  1.025  0.884  1.187  0.7478  1.109  0.921  1.334  0.2739  0.789  0.598  1.041  0.0939 
RORA rs4335725*         
BMP4 rs4898820  1.063  0.84  1.345  0.6107  1.117  0.846  1.475  0.4364  1.094  0.808  1.481  0.563 
ROBO1 rs1387665*      
BMP4 rs4898820  1.131  0.972  1.316  0.1124  1.188  0.987  1.43  0.0679  0.996  0.613  1.619  0.9887 
ROBO1 rs4513416*      
BMP4 rs4898820  0.932  0.8  1.086  0.3661  0.843  0.699  1.016  0.073  1.113  0.825  1.5  0.4832 
ROBO1 rs9309833*      
BMP4 rs4898820  1.009  0.851  1.196  0.9203  0.952  0.763  1.187  0.6603  1.104  0.816  1.495  0.5208 
* Summary of significant cases-only interaction analysis between the BMP4 SNPs and SNPs from the RORA-ROBO1-HTRA1 































Table 10: Example of OPLL Recording Sheet 
 
Collection Prevalence         
            
   From File                At Max    
                          
Number Extent Sex Race Age OPLL? Location  Type  Length  Width  Depth 
715  F WH 78 Y C3-7 S 13.15 3.7 1.37
1433 R F WH 78 Y C2-6 S 13.03 5.08 1.59
1219  M WH 79 Y C3-5 S 12.92 4.2 1.12
1461  F BL 80 Y C3-6 S 11.45 4.71 1.09
1445  M BL 80 Y C2-7 M 16.95 5.24 1.9
1635  F WH 81 Y C2-7 S 11.1 3.91 2.05
1502 R F WH 82 Y C3-4 S 15.7 3.43 1.55
1545  M WH 82 Y C3-4 S 14.7 3.51 1.39
76 R F WH 62 Y C3-4 S 11.14 3.45 1
951 R F WH 62 Y C3-4 C 13.25 4.48 2.35
726  M BL 62 Y C3-5 S 11.84 4.23 1.21
503  M BL 76 Y C3-6 S 14.53 6 1.96
278  M BL 76 Y C2-6 M 12.53 8.92 2.13
100 RR F BL 85 Y C3-6 S 12.51 5.09 2
1117  M BL 85 Y C3-5 S 12.32 5.35 1.91
748  M WH 85 Y C3-5 S 14 5.22 1.13
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